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ABSTRACT 
Affinity maturation increases the affinity of B-cell derived antibodies to their cognate 
antigens. In this study, we characterized the kinetic, structural, dynamic and 
thermodynamic evolution of antibodies during affinity maturation. Through single B-cell 
cell sorting, paired heavy and light chain sequencing, phylogenetic analysis, antibody 
expression, and physicochemical characterization, we were able to longitudinally analyze 
the stages of affinity maturation of anti-PA (B.anthracis protective antigen) antibodies. 
Following repeated immunizations, we observed up to an 10,000-fold increase in antibody 
affinity, mainly through a decrease in the off-rates. For detailed maturation analysis, we 
chose three antibodies lying along a single clonal branch--the clone’s unmutated common 
ancestor (UCA), a medium affinity antibody (MAAb) appearing after second 
immunization, and a high-affinity antibody (HAAb) appearing after third immunization. 
Most of the mutations that occur between the UCA and HAAb resulted in key changes to 
structural conformation. In particular, mutations change residues in the CDR-H3 region 
inducing the folding of the CDR-loops into a conformation that is more complementary to 
PA. This advantageous new antibody conformation is preserved in the unbound state, 
indicating that though the UCA and MAAb appear to use an induced fit and/or 
		 ix 
conformational selection mechanism, the HAAb is more rigidly lock-and-key. 
Thermodynamic results support this interpretation. In the first maturation step from UCA 
to MAAb, enthalpic improvement indicates optimization of noncovalent interactions. The 
second step from MAAb to HAAb predominantly involves entropic improvement by which 
the advantageous conformation made accessible in the first step is made more dominant 
via the narrowing of effectively accessible conformations, which allows better contact with 
PA. This is also reflected by a less significant improvement in the enthalpic component of 
PA-binding. Studies examining the evolving protein-dynamic characteristics further 
support this interpretation. In summary, we observed that a single energetic component is 
not responsible for increased affinity in the maturation pathways we studied. From UCA 
to MAAb, affinity increases through optimization of noncovalent interactions. From 
MAAb to HAAb, affinity increase is achieved through changes that stabilize the favorable 
conformation in the unbound state. A better understanding of affinity maturation can have 
implications for antibody engineering and vaccine development. 
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CHAPTER ONE: INTRODUCTION 
 
1.1 History of Adaptive Immune System. 
Infectious diseases have been a problem since the beginning of the humanity. The ancient 
Greeks had realized that a single exposure to a disease usually provided immunity against 
the same disease. As early as 1000 AD, the Chinese were immunizing themselves by taking 
scabs of smallpox from infected people, drying, mixing with a plant in powdered form, and 
blowing the mixture into their nose, a method dubbed variolation (1). A practice common 
in Eastern world, it only spread to the West in late 18th century, when Edward Jenner 
discovered that “vaccinating” with cowpox conferred immunity against smallpox in a safer 
manner than variolation (2). Half a century later, Louis Pasteur developed a vaccine against 
chicken cholera by chance, weakening the bacteria inadvertently and observing protection 
in the chicken against the disease (3). He applied the same method to develop an anthrax 
vaccine (3). By the 20th century, several vaccines were developed, including diphtheria, 
tuberculosis, whooping cough and tetanus among others. However, how the vaccines 
activate the immune system was still unknown as the vaccines have largely been developed 
empirically since those early days. 
The immune system consists of two arms, innate and adaptive immunity. The innate 
immune system acts as a first line of defense and recognizes conserved molecular patterns 
on microorganisms. On the other hand, adaptive immune system is specific to the particular 
pathogen and has a memory component where the response is more rapid upon exposure 
to the same pathogen. The adaptive immune system consists of antibody-mediated and cell-
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mediated responses.  
The attempts to understand the antibody-mediated arm of the adaptive response date back 
to the end of the 19th century. In 1897, Paul Ehrlich suggested a side-chain theory, which 
tried to explain the explosive increase in the antibody production in the body after antigen 
exposure (4). The side-chain theory postulated that white blood cells had several side-
chains on their surfaces that were selected based on their interaction with the toxin, 
triggering the amplification of that specific side chain which would later be released into 
the blood. A clever theory comprising that the information necessary for synthesizing all 
the antibodies was present in the genes, it was based on the lock-and-key concept of Emil 
Fischer, suggesting a highly specific interaction between the antigen and the antibody (5). 
This concept was proposed by Fischer to explain how the enzymes interacted with their 
glucoside substrates where the enzyme and the substrate were envisioned as rigid bodies 
with complementary surfaces. The side-chain theory, while revolutionary, failed to explain 
Landsteiner’s findings about antibody production against haptens, which are small 
artificial molecules, that the body could not have met before (6, 7). If chemists could 
synthesize artificial molecules that were not present on Earth before, how could that 
information be pre-encoded in a finite genome? In addition, could the body encompass an 
exorbitant number of receptors on the cell surface in order to account for the seemingly 
unlimited diversity of the antigens?  
In the 1930s, Breinl and Haurowitz, Mudd, Alexander and Pauling offered the instructionist 
theory as an attempt to explain how the immune system could respond to any molecule, 
whether natural or synthetic (8-11). The theory suggested that the antigens acted as 
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templates, “instructing” the antibodies into adopting the correct form. As a result, the 
number of antibodies would be determined by the number of antigens.  
However, the instructionist theory contradicted several immunological phenomena (12). 
During the initial response, the number of the antibodies increased; on the contrary, the 
number of the antigens decreased due to clearance, which led to a discrepancy with the 
theory according to which the antibodies could not outnumber the antigens. The longer 
life-time of the antibodies in the body compared to the antigens created an inconsistency, 
too. Also, if all the antigens were cleared, the secondary response would be expected to 
start from scratch each time the same antigen was encountered and follow a similar pattern 
to the primary response, yet it was known that the immunological memory resulted in a 
much more rapid response against that pathogen with each successive exposure. The 
instructionist theory could also not explain the affinity and specificity increases of the 
antibodies during the immune response which would not be expected from a template-
based mechanism.  
Niels Jerne addressed these issues from a natural selection perspective, with the idea that 
the antibodies might be selected by the antigens instead of being “instructed” (12). The 
antigen-antibody complex would then circulate in the body until a B-cell would take them 
and produce more of that antibody. This scenario would require each B-cell to have the 
capability to produce all kinds of different antibodies to multiply the internalized antibody, 
which is not feasible. Jerne’s theory would also require the transmission of the sequence 
information of the internalized antibody to the genetic material of the cell to produce more 
of that antibody. However, the emerging field of genetics showed the information flow to 
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be in the opposite direction, from the gene to the protein.  
Talmage and Burnet extended Jerne’s theory and suggested that the antigens bound to the 
receptors on the B-cells instead of the antibodies (13, 14). Burnet’s clonal selection theory 
postulated that the B-cells were preprogrammed to have a unique specificity; upon binding 
being bound by its specific antigen, the selected B-cell proliferated and produced a single 
type of the antibody which was the secreted form of the receptor on that B-cell. This 
preprogramming, Burnet speculated, involved somatic hypermutation of the antibody 
genes during lymphocyte generation to increase the diversity of the primary repertoire. As 
it was discovered two decades later, the diversity of the primary repertoire was actually 
coming from random recombination. Tonegawa demonstrated that the antibody genes of 
the B-cells were segments brought together to form a complete, functional gene, during 
which new sequences were added and/or deleted at the junction points of the segments, a 
process called V(D)J recombination (Figure 1.1) (15). The heavy chain family involves the 
V, D, J and C gene segments, where the VDJ segment encodes the heavy chain variable 
domain, while the C segment encodes the heavy chain constant domain. The light chain 
family, consisting of the kappa, κ and lambda, λ subfamilies, lacks the D segment, and uses 
the V and J segments to encode the light chain variable domain and the C segment to 
encode the light chain constant domain. During B-cell maturation, first the heavy chain 
variable region gets rearranged. One D and one J segment come together, followed by the 
joining of an upstream V segment. These joining processes are imprecise, introducing 
junctional diversity by trimming the coding joints as well as adding extra nucleotides to 
the ends. The gene segments between the selected segments are deleted during the 
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recombination event. The light chain is rearranged in a similar manner, where one V 
segment and one J segment are combined. The antibody primary transcript of the heavy 
chain also contains the constant regions µ (IgM) and ∂ (IgD). These constant regions later 
get switched to other classes, namely γ (IgG), ε (IgE) or α (IgA). The class switch 
recombination (CSR) process confers enhanced effector function onto the secondary 
repertoire antibodies. Together with somatic hypermutation, CSR provides protective 
humoral immunity to the host. 
Later investigation of several light chains from mouse demonstrated that the somatic 
hypermutation process envisioned by Burnet was indeed happening during the immune 
response, but rather to increase the diversity of the secondary repertoire that arises after 
exposure to the antigen (16). 
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Figure 1.1. A scheme showing the V(D)J recombination and combinatorial design of 
the antibody variable regions of IgG1 antibodies.  
 
 
1.2. Affinity Maturation. 
Antibodies consist of two heavy and two light chains, forming two identical Fab (fragment 
antigen binding) arms attached by a flexible hinge to the Fc (fragment crystallizable) 
domain (Figure 1.2).  
 
 
V-segments D-segments J-segments Constant region
D-to-J recombination
V-to-DJ recombination
Transcription & Splicing
Translation & assembly
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Figure 1.2. An IgG1 antibody diagram. The Fab arms bind the antigen and the Fc tail 
interacts with the Fc receptors on certain immune cells. 
 
The heavy chains differ in size and composition based on the antibody class. The IgG1 
class antibodies that arise during secondary response and comprise the majority of total 
serum immunoglobulins have four domains in their heavy chains and two domains in their 
light chains. Each heavy chain has an amino terminal variable domain (VH) followed by 
three constant domains, namely CH1, CH2, CH3. The light chains contain a variable (VL) 
and a constant (CL) domain. The variable and constant domains are repeated 
immunoglobulin folds consisting of β-sheets formed by β-strands packed against each 
other in an anti-parallel manner (17). The β-sheets are stabilized by hydrogen bonding 
between the strands, hydrophobic forces in the interior and a disulfide bond between the 
sheets. The variable domains include three highly variable CDR loops, distributed among 
framework regions that are more preserved (Figure 1.3). The CDRs provide the antigen 
specificity, where usually CDR-H3 is the main loop in antibody-antigen interactions. The 
FabFab
Fc
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constant domains on the other hand serve as a structural framework and have effector 
functions.  
 
 
Figure 1.3. Fab antibody variable domain structure and the secondary structures in 
a three-dimensional model. 
 
Originally, the naïve B-cells produce antibodies that have low affinity toward their antigen 
in their variable regions and limited effector functions, in the form of IgM, in their constant 
regions. Following activation, B and T cells that are specific to the antigen migrate to 
secondary lymphoid organs (18-20). There, the B-cells compete with each other to interact 
Constant	Region	(CH1)FW1 CDR-L1 CDR-L2 CDR-L3FW2 FW3 FW4
Light	Chain
Constant	Region	(CH1)FW1 CDR-H1 CDR-H2 CDR-H3FW2 FW3 FW4
Heavy	Chain
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with antigen-presenting cells such as follicular dendritic cells. The B-cells with surface 
antibodies that have relatively higher affinity to the antigen can internalize and present the 
digested antigen in higher quantities on their surfaces compared to the B-cells with lower 
affinity surface antibodies, attracting more follicular helper T cells. These higher-affinity 
B-cells receive signals from the helper T cells to proliferate, switch class and differentiate 
into antibody-secreting cells or memory B-cells. The germinal center reaction involves 
increasing the affinity of the selected B-cells through somatic hypermutation of the variable 
region genes at a rate of 103 per base per generation (21). This high rate of mutation, which 
is approximately a million-fold higher than the normal mutation rate in the body, enables 
the significant increase in antibody affinity to rapidly and potently respond to diverse 
pathogens (22). 
 
1.3. Mechanisms Underlying the Affinity Maturation. 
The need to respond to the pathogens efficiently and in a specific manner with minimum 
autoimmunity led Burnet to postulate “one cell produces one type of antibody” in his clonal 
selection theory. In the early years of the theory, studies were done to challenge this 
suggestion by showing that one B-cell could have dual specificity. A study by Nossal and 
Lederberg observed that antibody-producing cells from mice immunized with two non-
cross reactive strains of Salmonella bacteria were specific only to one type of antigen, not 
both as originally expected (23). Another study that immunized mice and rabbits with 
fluorescent antigens also could not find any single cells that detected both antigens (24). 
Landsteiner’s hypothesis of antibodies being able to react with a variety of ligands in an 
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affinity gradient got buried in the dusty pages of history, and the view that antibodies had 
single absolute specificity toward their cognate antigens and no recognition of any other 
molecule got cemented.  
This view, along with technical limitations, diverted the attention away from dynamic 
characterization of antibodies for many years as the hypothesis of interacting with one 
antigen in a specific manner had the implicit assumption of interacting in a lock-and-key 
fashion. As a result, the genetic and biochemical bases of affinity maturation have been 
well characterized over the years, while the biophysical aspects were not studied much 
until recently.  
With the advances in biophysics, it became clear that proteins are not static but dynamic 
entities (25). Realizing that dynamics may contribute to biological function, the structure-
function paradigm in biology has been expanded to include dynamics. Molecular 
recognition is the basis of almost all protein functions, and protein dynamics, related to 
protein flexibility, determines how the protein interacts with its partner. During the 20th 
century, the lock-and-key concept of Fischer got combined with flexibility and extended 
into two new concepts, namely induced fit and conformational selection. Koshland’s 
induced fit theory (26) can be seen as a type of the instructionist theory, which postulates 
that the substrate binding to the enzyme “instructs” a conformational change in the enzyme 
in order to obtain a steric fit between the two molecules. A competing theory to explain the 
conformational change after ligand binding came from Monod-Wyman-Changeux in 1965 
(27), who suggested that the various conformations were not induced by ligand binding but 
rather were present in the initial population of the enzymes and selected by the ligand to 
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form the most stable, lowest energy complex, shifting the equilibrium towards the bound 
state.  
If enzymes were able to sample various conformational states, could antibodies adopt 
different conformations as well? Transition among different conformational states in 
antibodies was first discovered 40 years ago during kinetic characterization of hapten-
specific immunoglobulin A molecules (28). A later study on IgG1 immunoglobulins 
recognizing the hapten 2-phenyl-5-oxazolone observed even more complex hapten binding 
kinetics (29). Structural proof for the existence of conformers came from an IgE antibody 
that was shown to adopt different unbound conformations by X-ray crystallography, 
enabling the molecule to interact with different molecules (30). This immunoglobulin was 
originally raised against a dinitrophenol hapten. In addition to recognizing various haptens, 
the antibody was also shown to bind a protein antigen that was selected through bacterial 
library screening. The authors crystallographically observed two different conformations 
in the unbound antibody, and two different conformations after binding either to the hapten 
or to the protein antigen, pointing out to a combined interaction model of conformational 
selection and induced fit. In another study, kinetic and equilibrium characterization of a 
single-chain variable fragment (scFv) indicated that the scFv recognized its peptide antigen 
by conformational selection (31). These studies confirmed that antibodies, like other 
proteins, are not static but dynamic entities that can adopt various conformations.  
A comparison of unmutated ancestor and mature antibodies was first attempted with X-ray 
crystallography of a catalytic hapten-specific antibody that showed an induced fit binding 
for unmutated ancestor while the mature antibody followed a lock-and-key binding (32). 
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Using three-pulse photon echo shift spectroscopy that characterizes fast timescale motions, 
as well as thermodynamic analyses of a group of antibodies, the Romesberg group 
suggested that the progenitor antibodies are flexible and hence, interact with their antigen 
via induced fit, while mature antibodies are rigid and favor a lock-and-key interaction mode 
with high specificity and affinity to a single partner (33, 34). Yet, these studies only focused 
on antibodies that recognize haptens. Haptens interact with antibodies through a different 
mechanism than protein antigens do. Haptens usually go into clefts, while protein antigens 
interact at the surface. Also, the techniques used were limited to femtoseconds-to-
nanoseconds motions such as bond vibrations and side chain rotations, ignoring the slower 
collective motions that are biologically relevant and have been shown to be important for 
antibodies. For example, Addis et al. characterized picomolar affinity antibodies and 
observed that their CDR3 domains sampled different conformations on a milliseconds 
timescale (35). These findings demonstrate that the biologically relevant long timescale 
dynamics of protein motion should also be considered to obtain a better understanding of 
the dynamic changes during affinity maturation.  
In this dissertation, paired-end sequencing of single B-cells from two individuals, each 
immunized five times with anthrax vaccine adsorbed (AVA) over a period of 18 months 
(Figure 1.4), gave us a unique opportunity to characterize the biophysical aspects of affinity 
maturation against a protein antigen in a comprehensive, in-depth and longitudinal manner, 
allowing us to observe the intermediate steps in the maturation pathway.  
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Figure 1.4. The AVA administration schedule. The vaccine was administered to two donors as 
per manufacturer directions, intramuscularly at 0, 1, 6, 12 and 18 months. 50 mL blood was 
collected one week after each immunization. V stands for visit. 
 
We characterized the kinetic maturation of the largest clone of each individual, and choose 
three anti-anthrax antibodies from the first subject for detailed analysis. We studied these 
three antibodies that show a direct lineage relationship, which were statistically assigned 
to the same clone with CloAnalyst, which also inferred the sequences of the unmutated 
common ancestor (UCA) and the intermediate antibodies in the clones (36). The UCA was 
observed experimentally as well, confirming the reliability of the inference of the 
sequences. We characterized the changes in the kinetics, structure, thermodynamics and 
dynamics of these antibodies to get a better understanding of how affinity maturation 
results in higher affinity in antibodies. This study has implications for vaccine and antibody 
design and development.
Subject
AVA	immunizations
Blood	draws
V1 V5 V8 V11 V14
Month 0 1 6 12 18
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CHAPTER TWO: KINETIC EVOLUTION DURING AFFINITY MATURATION 
 
2.1 Introduction. 
The development of the humoral immune response is characterized by affinity maturation 
((12, 22)), where the affinity improves several orders of magnitude (37, 38). Affinity 
determines how much ligand-analyte complex is formed at equilibrium, where association 
is in balance with dissociation. Kinetics, on the other hand, determines whether a complex 
forms or dissociates within a given timespan. On-rate/association rate determines how fast 
molecules bind, while off-rate/dissociation rate determines how fast complexes fall apart. 
Several mature antibodies have affinities toward their antigens in the range of 10-7 – 10-9 
M-1. Due to diffusion rates and the rate of receptor internalization upon antigen binding 
controlling the on- and off-rates, an affinity ceiling of ~10-10 M was predicted for antibody-
antigen interactions (39). Affinities above this threshold are presumed not to bring further 
advantage to the antibodies bearing this affinity over their lower affinity counterparts 
during the antibody selection process in vivo. Batista and Neuberger extended the affinity 
ceiling concept by designing an in vitro system to determine how the B cell response varies 
as a function of affinity (40). Antigen presentation was monitored through IL-2 secretion 
from lysozyme-specific T cell hybridomas cocultured with anti-lysozyme antibody 
transfectomas. The lifetime of the antibody-lysozyme complex was varied by mutations in 
the lysozyme. They determined a minimum affinity of 10-6 M for detectable B-cell 
triggering and found out the critical dissociation half-life as 12 minutes, where efficacy of 
antigen presentation fell significantly at half-lives shorter than 12 minutes. They observed 
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no improvement in antigen presentation when the half-lives were above 30 minutes.  
Just like the affinity of antibody–antigen interactions, their kinetics can vary by several 
orders of magnitude too. A seminal work on hapten-specific antibodies from primary, 
secondary and tertiary responses suggested that selection of high affinity antibody secreting 
B cells might be driven by faster on-rates rather than higher affinity (37). Recently, some 
other studies demonstrated affinity enhancement through faster on-rates. The unmutated 
ancestor sequence of an antibody against respiratory syncytial virus was determined and 
the mutations were reverted one-by-one to the ancestor sequence (41). Then, the 
association and dissociation rates of the variants were measured. The affinity increase was 
achieved through mutations in the CDR-H3 region that resulted in faster association rates. 
Recently, anti-HA antibodies were demonstrated to have around 40-fold increase in their 
association rates during affinity maturation, while the decrease in their dissociation rates 
was of lesser magnitude (42).  
On the other hand, several other studies observed affinity gains as a result of slower 
dissociation rates. Sagawa et al. measured the kinetics of a group of anti-(4-hydroxy-3-
nitrophenyl)acetyl monoclonal antibodies, where the antibodies were considered to belong 
to the same clone, and observed a decrease in both the association and dissociation rates in 
the mature antibodies compared to the less evolved ones (43). The affinity increase hence 
was attributed to slower dissociation rates. Klein et al. reverted the mutated residues of 
framework regions of several HIV-1 bnAbs to their unmutated ancestor sequences and 
showed that lower affinities primarily resulted from increased dissociation rates (44). 
Another HIV-1 antibody showed a slight increase in the on-rate but a huge decrease in the 
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off-rate when comparing the binding of the unmutated ancestor to the gp120 peptide with 
the antigen-binding of the mature Ab (45). Bonsignori et al. followed the developmental 
pathway of a CD4-mimicking antibody, where the significant increase in affinity was 
facilitated predominantly by slower dissociation rates (46). Kinetic analysis of an anti-
fluorescein antibody revealed a higher improvement in the dissociation rate compared to 
the association rate, where the hydrogen bonding introduced between the antigen-antibody 
pair by the mutations in the heavy chain was suggested to account for the improvement of 
both rates (34). Another study characterized the response against tetanus vaccination and a 
comparison of the Fab antibodies with their deduced unmutated ancestor showed an off-
rate maturation, where the on-rates were both positively and negatively affected by the 
mutations (47).  
These studies demonstrate that affinity can increase via improved association rates, 
improved dissociation rates or both. In this part of the dissertation, we characterized the 
kinetics of two clones from two different subjects who were vaccinated with the anthrax 
vaccine 5 times over a period of 18 months. Representative antibodies from different 
timepoints were selected and synthesized in mammalian cell cultures. The binding 
characteristics of these antibodies to anthrax protective antigen (PA) were analyzed with 
Surface Plasmon Resonance (SPR).  
 
2.1.1 Equilibrium and Kinetics Measurement Methods. 
Several methods have been employed to measure antibody affinity, ranging from enyzme-
linked immunosorbent assay (48) to microscale thermophoresis(49) to isothermal titration 
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calorimetry(50) to biolayer interferometry (BLI) (51) to surface plasmon resonance (52). 
While these techniques are all capable of equilibrium analysis, only SPR and BLI can 
measure the kinetics of the interaction in real-time. The advantage of SPR over BLI is its 
higher sensitivity. In an SPR experiment, the ligand is bound to the biosensor surface and 
the analyte flows above it through a microfluidic system (Figure 2.1). Upon binding of the 
analyte to the surface ligand, the mass at the surface increases which changes the refractive 
index of the surface. This change in the refractive index results in a shift in the angle of the 
incident light, which is measured in arbitrary response units (RU) that is proportional to 
the molecular mass at the surface. The changes in RU over time is fit to a mathematical 
model to obtain the kinetic rate and affinity parameters.  
SPR is capable of providing the association rate constant, ka (also known as on-rate, kon), 
the dissociation rate constant, kd (also known as off-rate, koff) and the equilibrium 
dissociation constant (KD).  
 
 
Figure 2.1. A model showing an SPR surface and the detection mechanism of the 
binding kinetics. 
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2.2 Experimental Protocol. 
2.2.1 Recombinant antibody synthesis 
Synthesis was carried out according to the protocol shared by Life Technologies. The 
antibody heavy and light chain variable region genes were first synthesized as DNA 
sequences by LakePharma, Inc. (Belmont, CA) or Blue Heron Biotech (Bothell, WA). 
LakePharma used the pcDNA3.3 mammalian expression vector. The leader and variable 
region heavy chain sequences synthesized by Blue Heron were cloned into the pFUSE-
CHIg plasmid (InvivoGen, San Diego, CA; pfuse-hchg1) and light chain sequences were 
cloned into the pFUSE2-CLIg plasmid (InvivoGen, pfuse2-hclk). Plasmids were 
transformed into a Zymo competent DH5α strain of E. coli (Zymo Research, Irvine, CA; 
T3007) for amplification and incubated overnight at 37°C on LB agar plates with ampicillin 
(pcDNA3.3), zeocin (pFUSE-CHIg) or blasticidin (pFUSE2-CLIg). Single colonies were 
picked and the plasmids were purified using the PureLink HiPure Plasmid Filter Miniprep 
Kit (Life Technologies). The sequences were verified by Sanger sequencing (Beckman 
Coulter). The large-scale amplification was done in 1 liter LB cultures with the appropriate 
antibiotics and the plasmids were isolated with the PureLink HiPure Plasmid Filter 
Maxiprep Kit (Life Technologies). FreeStyle 293F cells (Life Technologies) were 
passaged between three and five cycles after thawing. Transfections for 30 ml ~1.0x106 
cultures were done with a mixture of 37.5 µL MAX reagent diluted in 600 µL Opti-MEM® 
I and 37.5 µg of heavy:light chain plasmid mixtures diluted in 600 µL Opti-MEM® I after 
10 minutes room temperature incubation. For larger culture volumes, the amounts were 
scaled-up accordingly. The heavy:light chain plasmid ratios were 1:1 for pcDNA3.3 and 
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2:3 for pFUSE. Transfected cells were incubated on a shaker (130-135 RPM) for four days 
at 37°C with 8% CO2. Cells were harvested by centrifugation for 1 hour at 4000X g at 
10°C. Antibodies were purified using Nab Protein A/G Spin Columns (Thermo Fisher 
Scientific) following manufacturer protocols. Briefly, columns were equilibrated to room 
temperature and storage solution was removed by centrifugation. All the centrifuging steps 
were done at 1000X g speed. The columns were prepared by washing them with and 
centrifuging out the binding buffer for 1 minute. Samples were diluted to 2mL in binding 
buffer and incubated with constant mixing in the columns for 10 minutes. Columns were 
then centrifuged for 1 minute and the flowthrough was discarded. Two additional binding 
buffer washes were done as before, discarding the flow-through. Samples were eluted by 
adding elution buffer and centrifuging for 1 minute into a new collection tube. The elution 
is repeated in two new collection tubes each, for three total elution fractions per sample. 
The antibody fractions were identified by SDS-PAGE and concentration with NanoDrop 
(Thermo Fisher).  
 
2.2.2 Surface plasmon resonance 
The affinities of the synthesized antibodies were measured using the Pioneer COOH2 
biosensor (Pall BioForte). COOH2 chips were coated first with Protein G (Sigma-Aldrich) 
in 10mM acetate buffer (pH 4.5) (BioRad) following the standard EDC/NHS coupling 
chemistry provided by the manufacturer. Antibodies were then diluted 1:1000 in 0.05% 
PBST and flowed over the chip. Antibodies were bound to protein G in a directional 
manner. The binding of anthrax recombinant Protective Antigen with the antibodies was 
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tested at six concentrations varying from 1.94µM to 0 nM with two-fold dilutions, based 
on the affinity of the antibodies determined by preliminary testing. All experiments were 
performed at 25°C, with the sample compartment set to 10°C. The flow rate was 40µl/min 
to minimize mass transport effects. The raw data were background-corrected using Qdat 
software (Pall BioForte) and then exported as text files. The analysis was carried out with 
the in-house developed Markov-Chain Monte Carlo methodology, SPRDesign 
(http://www.bu.edu/computationalimmunology/research/ software/). SPRDesign has a 4-
state model that accounts for conformational changes happening during binding. This 
model was used during the fitting. 
 
2.3. Results. 
The clone c1726 from subject 1 starts after the second immunization and lasts until after 
the fifth immunization (Figure 2.2). On the other hand, the clone c2202 from subject 2, 
which is the largest clone observed among the two subjects, appears after the third 
immunization and disappears after the fourth immunization (Figure 2.3). In both clones, 
the affinity increases from micromolar to picomolar levels in response to repeated 
vaccination (Table 2.1). The clone c1726 starts with ~1.5 µM affinity and goes up to 187 
pM affinity, while clone c2202 starts with ~0.5 µM affinity and goes up to 63 pM affinity, 
with both clones demonstrating a nearly 10,000-fold increase in affinity. This increase in 
affinity is mainly through off-rate maturation, where the dissociation of the antigen and the 
antibody becomes slower as a result of the acquired mutations. The increase in the on-rates 
is subtle, 5-fold in the S1c1726 clone and 10-fold in the S2c2202 clone. Some intermediate 
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antibodies have even slower association rates than their predecessors. UCAs of both clones 
display a fast association rate that is maintained across the later antibodies, suggesting that 
maintaining the fast association rate was important for the survival and maturation of these 
clones. The fastest off-rate belongs to the UCA of the S1c1726 clone and is around 0.9x10-
1 sec-1. The c8571S1 antibody coming next has an off-rate of 1.06x10-3, which is 85-fold 
higher than the off-rate of the UCA. This rate translates roughly as a 10-min half-life. The 
off-rate of the S2c2202-UCA is 7.3x10-3 sec-1, while the immediate descendant has a 4-
fold higher off-rate. So, the half-life increases from 1.6 min to 6.4 min. These half-lives 
are still shorter than the 12-minutes half-time estimated by Batista and Neuberger to bring 
advantage during clonal selection (40). The sequences in both clones that arose after the 
third immunization have all off-rates above 12-minutes. This might explain why the clones 
contract after the third immunization as further decrease in the off-rates would not improve 
the chances of selection of those sequences, but the additional mutations can be deleterious 
and decrease the affinity or stability. The off-rates go down to the 10-5 levels at the most 
mature antibodies, which provides more than 19 hours of complex half-life.  
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Figure 2.2. Clone c1726. Different colors indicate after which immunization the sequences were 
observed. 
 
Interestingly, the affinity does not exhibit a continuous improvement. Sequence 
c8090S1V8, which is a direct descendant of i12, has an 8-fold lower affinity. Again, i20 of 
clone S2c2202, despite arising later during the affinity maturation process, has a lower 
affinity than its precursors i54, i60 and the UCA due to an increase in its off-rate. All except 
one antibody have KD values larger than 100 picomolars, which is the affinity ceiling 
suggested by Foote and Eisen (39). The c4077S2V11 antibody that arises after 4th 
immunization has an affinity of 63 picomolars, breaking the affinity ceiling. While this 
affinity might not have brought any selective advantage during the selection process, there 
is nothing against reaching such high affinities either and they might occur by chance.   
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Figure 2.3. Clone c2202. Different colors indicate after which immunization the sequences were 
observed. 
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Table 2.1. The on-rates, off-rates and affinity values from the two clones. The values are 
obtained by fitting the experimental data (Figure 2.4) with SPRDesign. 
 
 
 
 
 
 
Clone	S1c1726 KD	(M) on-rates	(1/sec*M) off-rates	(1/sec)
UCA 1.50E-06 5.99E+04 9.06E-02
c8571S1V8 6.74E-08 1.58E+04 1.06E-03
i5_c1726 2.14E-09 8.85E+04 1.89E-04
c8106S1V8 1.63E-10 9.75E+04 1.59E-05
i12_c1726 1.01E-10 2.69E+05 2.73E-05
c8090S1V8 1.26E-09 9.07E+04 1.15E-04
c8075S1V8 8.40E-10 3.17E+05 2.38E-05
c5700S1V14 1.87E-10 1.31E+05 2.11E-05
c5315S1V14 7.70E-10 3.83E+04 2.98E-05
5
Clone	S2c2202 KD	(M) on-rates	(1/sec*M) off-rates	(1/sec)
UCA_c2202 4.20E-07 1.70E+04 7.30E-03
i60_c2202 1.64E-08 1.09E+05 1.80E-03
c7310S2V8 2.61E-09 4.24E+04 1.11E-04
i54_c2202 4.27E-09 4.72E+04 2.01E-04
c7364S2V8 1.30E-10 1.90E+05 2.47E-05
i20_c2202 1.60E-07 3.21E+04 5.15E-03
c4087S2V11 1.33E-10 9.64E+04 1.28E-05
i8_c2202 3.18E-08 1.54E+05 4.91E-03
c4126S2V11 1.37E-10 2.01E+05 2.75E-05
c4077S2V11 6.33E-11 1.67E+05 1.05E-05
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Figure 2.4. a) SPR sensorgrams of the antibodies from the S1c1726 clone. Black curves 
represent the data, red curves represent the fits. 
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Figure 2.4. b) SPR sensorgrams of the antibodies from the S2c2202 clone. Black curves 
represent the data, red curves represent the fits. 
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2.4 Discussion. 
The analysis of the SPR data shows an up to 10,000-fold affinity enhancement from the 
UCAs to the highest affinity counterparts. The affinity values of the UCAs from each clone 
are already in the micromolar range, which was determined by Batista and Neuberger as 
the minimum affinity for detectable B-cell triggering in their in vitro system, indicating 
that these antibodies might have gotten the edge during the clonal competition. 
The affinity enhancement is mainly through a decrease in the off-rates, with subtle 
increases observed in on-rates (Figure 2.5). Some antibodies even have slightly lower on-
rates than their predecessors. Long-range electrostatic interactions have been shown to play 
an important role in bringing the binding partners together, determining the on-rates (53, 
54). These interactions might be stronger for some antibody-antigen pairs and weaker for 
others, affecting the on-rates. However, all on-rates are still rapid, being in the order of 10-
4 – 10-5 M-1sec-1.  
Unlike the small changes in the on-rates, the off-rates decrease nearly 100-fold from the 
UCA to the MAAb, and another 100-fold from the MAAb to the HAAb. Off-rates are 
thought to be affected by short-range interactions which lock the two molecules together 
(53). So, the decrease in the off-rates might be contributed by the antibodies becoming 
better at interacting with the antigen as a result of affinity maturation. 
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Figure 2.5. Representation of the changes in on- and off-rates during affinity maturation of 
the two clones in response to anthrax vaccination. 
 
The observation that the on-rates did not vary significantly between vaccinations indicates 
that this parameter was already mature in the UCAs of both clones. In contrast, the off-
rates improved significantly after the second immunization in clone c1726 from subject 1; 
not changing much with consecutive immunizations. The off-rates of the sequences from 
clone c2202 from subject 2 were already slow after the third immunization when they first 
appeared, although a further slight decrease is observed after the fourth immunization.  
Thus, for both donors, the clones appear to be fully mature after the third immunization, 
regardless of their first appearance. The observed kinetic rate constants seem to have 
matured independently from each other, suggesting maturation of antibody responses is 
not thermodynamically but kinetically controlled, in line with Foote and Eisen that clonal 
selection by on- and off-rates occurs through independent mechanisms (39). 
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CHAPTER THREE: STRUCTURAL EVOLUTION DURING AFFINITY 
MATURATION 
 
3.1 Introduction. 
X-ray crystallography is a technique to visualize protein structures at the atomic level. 
Crystal structures can provide snapshots of the antibody structure during affinity 
maturation that enable the identification of key structural features to understand the basis 
for improved affinity and specificity.  
A number of structural studies have delineated the affinity maturation process of 
antibodies. For antibody-hapten interactions, it was found that the mutations in the CDR 
regions allowed the formation of additional interactions, such as hydrogen bonding, 
electrostatic and van der Waals interactions to increase affinity in the mature antibodies. 
The putative contact residues determined by an anti-2-phenyloxalozone antibody were 
shown to be preserved in several other anti-2-phenyloxalozone antibody sequences (55). 
The contact residues of an antibody-arsonate complex were also observed to be preserved 
(56). While conservation of contact residues is expected, not all mutations deemed 
significant in hapten-antibody interactions were at contact residues. The CDR-1 and CDR-
2 regions in the light chain of the anti-arsonate antibody were interacting with the CDR-3 
region of the heavy chain, hence mutations in those regions altered the conformation of the 
H3 loop (57). Other hapten studies demonstrated conformational changes as well. A mature 
antibody against 4-hydroxy-3-nitrophenyl acetate was shown to interact with the hapten 
via a deep hydrophobic pocket. A key mutation in the CDR-H1 region resulted in a smaller 
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side chain in the pocket, allowing better shape complementarity with the antigen; while 
another mutation in the CDR-H3 region affected the loop conformation. A mature 
nitrophenyl phosphonate antibody, which had a 30.000-fold increased affinity compared 
to the precursor antibody, was able to form additional hydrogen bonds, salt bridges and 
aromatic interactions with the hapten. In addition, the paratope of the mature antibody was 
stabilized into a conformation that was ideally suited to bind the hapten (32). To sum up, 
anti-hapten antibody affinity maturation appears to occur through a fine-tuning of the 
paratope complementarity which allows formation of new interactions. 
As the physicochemical properties of haptens as well as their antibody binding mechanisms 
are different than that of proteins, the question whether antibody-protein antigen pairs 
behave in a similar way during affinity maturation was raised. A study that characterized 
the binding of a humanized murine antibody to a model protein antigen, hen egg lysozyme, 
demonstrated that the increase in affinity towards this antigen was not due to the formation 
of additional bonds, unlike hapten-specific antibodies, but rather increased burial of apolar 
surface and improved shape complementarity at the heavy chain-antigen interface that 
facilitated hydrophobic interactions (58).  
A more recent study characterized the affinity maturation pathway of human antibodies 
against the influenza virus hemagglutinin (HA) (42). This is the first study in the field that 
used single B-cell sorting, deep sequencing and accurate clonal assignment on samples 
from a vaccinated subject and followed the affinity maturation of a small clone with five 
members. Through crystallography and long molecular dynamics studies, they observed 
that the affinity increase in these mature antibodies was achieved by increased 
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conformational rigidity in the CDR-H3 loop, which accounted for most of the affinity gain, 
as a result of mutations outside the binding loop. The antibodies in this study, however, 
were broadly neutralizing antibodies. Broadly neutralizing antibodies have different 
structural characteristics than normal antibodies, and their maturation pathways might not 
represent the affinity maturation of normal antibodies. 
In this part of the dissertation, we are characterizing the structural aspects of affinity 
maturation in a human subject responding to a bacterial vaccine, anthrax vaccine adsorbed, 
that is applied several times and analyze multiple stages of the maturation pathway. For 
this purpose, we solved the crystal structures of three anti-anthrax protective antigen (PA) 
antibodies, which represent different steps throughout the affinity maturation pathway 
from the unmutated common ancestor (UCA) c8812S1V5, through an intermediate, 
medium affinity antibody c8571S1V5 (MAAb), to a high affinity, mature antibody 
c8106S1V8 (HAAb) (Figure 3.1). Additionally, we solved the crystal structure of the 
HAAb-PA complex to determine the epitope recognized by these antibodies. We 
determined the non-covalent bonds formed between the antigen and the antibody, as well 
as calculated the buried surface area (BSA) and shape complementarity (SC) (59) between 
them. As non-covalent interactions play an important role in antibody-antigen binding, let 
us have a closer look at these interactions.  
 
3.1.1 Non-covalent interactions. 
The non-covalent interactions include hydrogen bonding, van der Waals forces, 
hydrophobic interactions and electrostatic interactions. The strengths of these interactions 
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vary between ~0.1-5 kcal/mol. While individually these weak interactions do not contribute 
much to the specificity, through simultaneous action of several of them, a high degree of 
specificity between the antigen and the antibody can be attained. Shape complementarity 
between two molecules is therefore important to maximize these non-covalent interactions. 
Hydrogen bonds are formed when a hydrogen atom is shared between two electronegative 
atoms. The donor shares its electropositive hydrogen electrostatically with the lone electron 
pair of the acceptor atom. Polar amino acid side chains, the carbonyl oxygen and amide 
groups can all act as donors or acceptors. 
Van der Waals interactions are weak, short-range noncovalent interactions that can either 
be attractive or repulsive based on the distance between the two molecules. They are 
defined as interactions between two molecules occurring through temporary fluctuating 
dipoles. Protein-ligand systems involve multiple van der Waals interactions which makes 
their contribution to protein energetics significant. 
Hydrophobic interactions occur when non-polar residues dislocate the water and interact 
with each other. As the non-polar residues cannot form hydrogen bonds with water, water 
molecules are forced to interact among each other and form ordered cage-like structures 
around the non-polar residues to satisfy their hydrogen bonding potential. The entropy of 
cage-like structured water is lower than the bulk water and hence unfavorable. 
Attractive electrostatic interactions are formed between oppositely charged residues 
located at <4Å than each other. These interactions are called salt bridges; they involve the 
amino and carboxy-terminals and ionizable side chains of positively-charged residues like 
lysine, arginine and histidine, and negatively-charged residues aspartate and glutamate. As 
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the interior of a protein has a lower dielectric constant due to the absence of water, the 
strength of the interior salt bridges is higher.  
 
3.2 Experimental Protocol. 
A general overview of solving a molecular structure by X-ray crystallography is provided 
in Figure 3.2. Basically, once a crystal is obtained, it is flash-frozen in liquid nitrogen, if 
necessary the crystal can be treated with a cryoprotectant solution. Next, it is exposed to 
X-rays, which provides several two-dimensional diffraction patterns corresponding to 
different crystal orientations. The two-dimensional patterns are then combined into a three-
dimensional lattice that is converted into a three-dimensional structural model through 
Fourier Transform of amplitudes derived from observed intensities and phase information 
obtained via homology modeling. Models are improved through iterative cycles of 
structural refinement and manual rebuilding. 
The purified Fab fragments in a buffer of 20 mM HEPES, 150 mM NaCl, pH 7.4 were 
concentrated to 15-25 mg/ml for crystallization trials. Crystals were grown at 20°C by 
hanging-drop vapor diffusion by mixing equal volumes of protein and well solution (0.05M 
glycine, 24% (w/v) PEG3350 (pH 9.5) for the UCA Fab, 0.01M ZnSO4, 18% (v/v) PEG 
MME 550, 0.1M MES (pH 6.5) for the MAAb Fab, 20% (v/v) ethylene glycol, 15% (w/v) 
PEG3350 for the mature Fab, and 0.3M citrate (pH 7.0), 24% (w/v) PEG for the HAAb-
PA complex) on siliconized glass coverslips that were inverted over with a well solution. 
Crystal growth proceeded at 20°C over the course of several weeks. 
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Figure 3.1. The phylogenetic tree to which the three anti-anthrax antibodies belong. The three 
antibodies are highlighted in pink boxes with the path from the UCA to the high affinity antibody 
delineated in pink. The box on the right shows after which immunization the sequences were 
isolated. Green, cyan, purple and pink sequences were isolated one week after second, third, fourth 
and fifth immunizations, respectively.  
 
The UCA Fab and the mature Fab-PA crystals were cryoprotected by soaking in 8:3 well 
solution: 85% glycerol, while the MAAb Fab and HAAb Fab crystals were flash-frozen 
without additional cryoprotection. Data collection was performed at Advanced Photon 
Source GM/CA beamlines 23ID-D. Data collection used a 10 µm beam and diffraction 
images were collected in 0.5° oscillations at a wavelength of 1.033 Å. The data were 
imm#
2
3
4
5
UCA
I6
I12
I7
I8
c8812S1V5
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integrated with XDS (60) and space group determination and scaling were performed with 
Pointless and Aimless from CCP4 (61). The structures were determined by molecular 
replacement with Phaser-MR using the atomic coordinates of a human germline Fab 
antibody(62) as the search model for the mature Fab, and later using the solved mature Fab 
structure for the rest of the antibodies. Initial phases were calculated using a model that 
lacked the CDR-H3 loop, and density modification was carried out using Phaser with NCS 
where appropriate to reduce phase bias. The CDR-H3 loop was then rebuilt into this 
density. The model was further rebuilt with iterative cycles of manual rebuilding in 
COOT(63) and refinement with phenix.refine (www.phenix-online.org). The refined 
structures were visualized with Swiss-PdbViewer (http://spdbv.vital-it.ch) and PyMOL 
(http://www.pymol.org/). Since the UCA and the MAAb Fab failed to crystallize in 
complex with PA, the Fab structures were superimposed onto the HAAb coordinates in the 
Fab-antigen complex to provide a reasonable model for the interaction of these antibodies 
with the PA antigen. This part of the thesis was done in collaboration with Dr. Michael J. 
Rynkiewicz from the Department of Physiology & Biophysics of Boston University.  
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Figure 3.2. Steps of solving a molecular structure by X-ray crystallography.  
 
3.3 Results. 
Compared to the UCA, MAAb incorporates 2 mutations in its heavy chain, S35I and G99A, 
and 1 mutation in its light chain, Y94F (Figure 3.3). These mutations result in an 
approximate affinity increase of 25-fold (Table 1). The first inferred antibody, I8, has 4 
more mutations in the heavy chain compared to the MAAb. I7 has the same heavy chain 
sequence as the I8, but incorporates a light chain mutation, S95P. In I6, we see that the 35th 
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residue gets mutated into methionine, while A99 reverts to glycine as was the case in the 
UCA. Finally, the HAAb gets additional 5 mutations in the heavy chain and 1 mutation in 
the light chain. Also, V102 mutates into isoleucine. At this step, the affinity increases 
nearly 400-fold. Compared to the UCA, the HAAb has 9 mutations in its heavy chain and 
3 mutations in its light chain, with a total of ~10,000-fold affinity increase.  
 
 
Table 3.1. The numbers of mutations and affinities of the antibodies. 
 
	
Antibody # of Mutations in Heavy chain # of Mutations in Light chain Affinity (nM) 
8812V5 Baseline Baseline 1500  
8571V5 2 1 67.4 
8106V8 9 3 0.16 
UCA
MAAb
HAAb
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We crystallized the three antibodies as Fab fragments in an unbound state as well as the 
HAAb in complex with PA. The resolutions of the UCA, MAAb and HAAb are 2.6 Å, 2.61 
Å, and 2.39 Å, respectively. The resolution of the HAAb-PA complex is 2.5 Å. The 
statistics of the diffraction data and the model are shown in Table 3.2. The final models 
show good geometry and agreement to the observed diffraction data (Figure 3.4). For 
buried surface area and shape complementarity calculations, we superimposed the UCA 
and the MAAb onto the mature antibody of the HAAb-PA complex structure.  
 
3.3.1 The antigen binding site is mostly conserved in the 3 Fabs, with the exception of the 
CDR-H3 loop 
The antigen binding site was determined from the crystal structure of the HAAb-PA 
complex and is mostly conserved as can be seen from the superimposed models of the three 
antibodies (Figure 3.5). The exception is the H3 loop, where mutations occurring during 
affinity maturation give rise to different conformations (Figure 3.6). It is important to 
mention that the observed H3 loop conformation might be influenced by a crystal contact 
in the UCA structure. However, the fact that it can adopt such an extended conformation 
confirms the flexibility of the loop. 
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Table 3.2. Crystallographic data table with structure refinement statistics. 
 
 
 
Item UCA MAAb HAAb HAAb-PA 
complex 
Data Collection 
Space Group  P 21 I 2  I 2  P 1 
Unit Cell 
Dimensions 
a= 69.281 Å, 
b=70.858 Å,   
c=90.035 Å,  
β=93.85°  
a=78.790 Å,   
b=61.788 Å,   
c=110.188 Å,    
β=93.73°   
a=77.836 Å, 
b=132.257 Å,   
c=94.321 Å,  
β=96.24°   
a=65.223 Å,  
b=91.277 Å, 
c=147.711 Å, 
α=107.82°,  
β=93.80°,    
γ=90.17° 
Resolution 50-2.6 Å  
(2.71-2.6 Å) 
27.98 – 2.61 Å  
(2.81 – 2.61 Å) 
29.29 – 2.39 Å 
(2.48 – 2.39 Å) 
49.469 – 2.50 Å 
(2.56 – 2.50 Å) 
Number of 
reflections 
31538 (2780) 14488 (1991) 36544 (3754) 104179 (3787) 
Wavelength 1.03320 Å 1.03320 Å 1.03320 Å 1.03320 Å 
I/σ(I) 10.7 (2.2) 12.9 (2.2) 14.81 (3.6) 7.44 (1.57) 
Completeness 95.2 % (77.6 %) 99.3 % (99.2 %) 99.7 % (90.4 %) 92.5 % (56.3 
%) 
Redundancy 3.3 (3.2) 3.5 (3.3) 3.4 (3.4) 1.9 (1.7) 
Rmerg e 0.070 (0.200) 0.055 (0.422) 0.048 (0.272) 0.101 (0.764) 
CC½ 0.99 (0.524) 0.998 (0.912) 0.997 (0.984) 0.995 (0.373) 
Refinement 
Rwo rk 0.2093 0.2274  0.2367  0.2384  
Rfree 0.2432 0.2690 0.2691 0.2611 
Number of protein 
atoms 
6359 3180 6407 16576 
Number of waters 146 11 289 89 
Number of other 
atoms 
12 3 0 2 
Average B factors 
Protein 29.07 89.04 45.59 76.22 
Solvent 27.61 70.20 41.33 52.82 
R.m.s.d. from Ideal Values 
Bond lengths (Å) 0.002 0.002 0.002 0.003 
Bond angles (°) 0.573 0.483       0.504 0.496       
Chiral volume (Å3) 0.042    0.039    0.041    0.042    
Ramachandran Plot 
Favored 98.08 % 95.91 %                                                97.13 % 96.48 %                                                
Allowed 1.92  % 3.61  %                                                2.87 % 3.33  %                                                
Outliers 0.00  % 0.48  %  0.00  % 0.19  %                                                 
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Figure 3.4. a) Electron density map (2Fobs-Fcalc) of the heavy chain CDR loops of the three 
antibodies and contoured at 1 sigma. 
 
 
 
 
 
Electron density map calculated using Fourier coefficients 
using 2Fobs-Fcalc and contoured at 1 sigma.
UCA Medium Affinity Ab Mature Ab
CDR-H1
CDR-H2
CDR-H3
MAAb HAAb
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Figure 3.4. b) Electron density map (2Fobs-Fcalc) of the light chain CDR loops of the three 
antibodies and contoured at 1 sigma. 
 
 
 
Electron density map calculated using Fourier coefficients 
using 2Fobs-Fcalc and contoured at 1 sigma.
UCA Medium Affinity Ab Mature Ab
CDR-L1
CDR-L2
CDR-L3
C MAAb HAAb
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Figure 3.5. The superimposition of the three Fab antibodies. The UCA is in yellow, the MAAb 
is in green, and the HAAb is in purple. The heavy chains in the right side (VH) are in bright colors, 
while the light chains on the left side (VL) are in dull colors. Pymol was used to draw and visualize 
the structures (64). 
 
CDR-H3
VL VH
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Figure 3.6. A zoom-in on the CDR-H3 loops of the three antibodies. The left figure compares 
the UCA (in yellow) with the MAAb antibody (in green), while the right figure shows the 
differences in the CDR-H3 loop between the MAAb and the HAAb (in purple). 
 
3.3.2 The contact residues between the HAAb and the PA antigen 
The crystal structure of the HAAb-PA complex allows the determination of the epitope 
(Figure 3.7). The HAAb binds to protrusions on the antigen surface in domains 1 and 3 of 
PA. Protective antigen consists of 4 domains. Each domain has a different role. The amino-
terminal domain 1 contains a furin cleavage site and two calcium-binding sites. The 
calcium binding sites play a role in the folding and stabilization of the PA (65). Upon 
cleavage of part of domain 1 (residues 1-167), domains 2 and 3 form heptameric pores in 
the cell membrane (66, 67), acting as a translocation gate for the other toxin molecules of 
the anthrax. The carboxy-terminal domain 4 is involved in host receptor binding (68). 
UCA MAAb HAAb
CDR-H3 CDR-H3
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The residues in domain 1 of the PA that interact with the antibodies are close to the furin 
cleavage site (Figure 3.7, lower right). Antibody binding might interfere with the cleavage 
of domain 1 by sterically hindering the binding of furin. Several aspartate residues among 
others in domain 1 coordinate Ca+2. While none of the calcium-binding PA residues interact 
with the antibody, the microenvironment might be affected by the interaction of residue 
R178 with the antibody as the calcium binding residues are either connected to R178 or 
close to it. Potentially, the interaction between R178 and the antibody might affect the 
stability of the PA antigen upon antibody binding.  
The antibody and antigen make several specific contacts between the heavy and light 
chains and the PA antigen. The R178 of PA, which appears to be a key recognition element 
in the PA for the antibodies, forms salt bridges with residues H-D106 and L-E55, as well 
as hydrogen bonds to the polar, not charged residue H-T104 and to the polar, charged 
residue L-K50. In addition, it forms a cation-p bond with L-49Y. Another salt bridge 
formed within domain 1 is between the residues E224 and L-K50. Residues V189 and P223 
form van der Waals contacts with H-Y32 and H-M100, respectively. The non-polar 
residues P510, P513, L514 engage with H-Y59, L-F94, L-W32, respectively, through van 
der Waals interactions. Domain 3 residue T516 forms a hydrogen bond with H-I102, while 
D520 forms a hydrogen bond with H-S54. All six CDR loops form interactions with the 
PA; however, the majority of the interaction interface is comprised by the CDR-H3 and 
CDR-L3 loops, with two key interactions from the CDR-L2 loop.  
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Figure 3.7. Mature antibody in complex with the anthrax protective antigen and the epitope 
residues highlighted. The mature antibody light chain (pink) and heavy chain (purple) are 
displayed as ribbons. The PA is shown as a molecular surface colored by domain – domain 1 (gray), 
domain 2 (yellow), domain 3 (cyan), and domain 4 (green). Close-up view of the antigen binding 
site, with antibody side chains making contacts to PA in the structure displayed as sticks (right 
side). Amino acid sequence of PA with domains colored as above and the interacting residues 
highlighted in red boxes. The furin cleavage site is shown in the black box (bottom). 
 
  
MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSEL
ENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKG
LDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWIS
NIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAARIIYPIVHVDMENIILSKNEDQSTQNTD
SQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNA
NIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLE
LEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTFNGKDLNLVERRIAAVNPSDPLETTKPDMTLK
EALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRNNI
AVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYN
DKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
Heavy	Chain
Light	Chain
Domain	1
Domain	2
Domain	3
Domain	4
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3.3.3  Antibody evolution pattern during affinity maturation 
The crystal structures, along with the maturation pathway (Figure 3.8), allow us to correlate 
the amino acid mutations with the structural changes these mutations would create, 
elucidating the affinity maturation process.  
 
 
Figure 3.8. The evolutionary maturation pathway along with relevant mutations. 
 
Three mutations are incorporated in the first step in the phylogenetic tree from the UCA to 
the MAAb antibody, namely H-S35I, H-G99A, and L-Y94F. Comparing the two 
structures, we can predict the structural effects of these mutations (Figure 3.9). The heavy 
chain mutations H-S35I and H-G99A seem to influence the H3 loop conformation. The H-
S35I mutation (Figure 3.9, upper left) provides a more hydrophobic environment for H-
F104 to pack against, favoring the H3 loop conformation observed in the MAAb over that 
observed in the UCA. The substitution of H-G99 with alanine reduces the conformational 
flexibility of the backbone, as glycine has a higher flexibility than alanine due to lacking a 
side chain. As a result, the loop folds differently (Figure 3.9, upper right). This H3 loop 
conformation is more optimized to contact the PA and may explain the increased affinity 
UCA
I24
L-Y94F
H-S35I
H-G99A
I8
H-A50G
H-S57N
H-A102V
H-Y107N
I5
I7
L-S95P
I6
c7865S1V8
H-I35M
H-A99G
Mature	Ab
L-T85S
H-G10D	
H-M34L	
H-S85T	
H-V93I	
H-K98Q	
H-V102I	
H-N107Y
Medium	affinity	Ab
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of the MAAb towards the antigen. The mutations may also reduce the conformational 
flexibility of the H3 loop and start to move antigen binding away from induced 
fit/conformational selection mechanisms to a lock-and-key mechanism. L-Y94 residue 
forms van der Waals interactions with PA-P513. However, this residue is too close to PA-
T516 due to its sticking hydroxyl group. The L-Y94F mutation in this residue may allow 
the antibody to come closer to the antigen as phenylalanine has a smaller side chain 
compared to tyrosine, enabling more contact between the two proteins (Figure 3.9, lower 
left). So, L-Y94F occurs very early in the phylogenetic tree and is preserved throughout 
the maturation process on all sequences, including the sequences not shown here.  
 
 
Figure 3.9. Structural analysis of the key mutations converting the UCA to the MAAb. The 
antibody crystal structures are shown as stick representation of the UCA (yellow), MAAb (green), 
HAAb (purple) and PA (blue). The mutations in the tree are shown for each panel. 
H-S35I
CDR-H3
L-Y94F
PA-T516
H-G99A
H-F105
UCA
H-S35I
H-G99A
L-Y94F
I24
PA-P513
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Next, the antibody incorporates four mutations transitioning from the MAAb to the inferred 
sequence I8. Two of the mutations are involved in H3 loop conformation, namely H-A50G 
and H-A102V. H-G50 along with the previous isoleucine incorporated at the 35th position 
create a hydrophobic pocket into which the V102 side chain can suit itself better due to the 
smaller side chain of glycine compared to alanine (Figure 3.10, upper left). These 
mutations stabilize the H3 loop in a new conformation (Figure 3.10, upper right). 
Asparagine is more polar than both tyrosine and serine. The H-Y107N and the H-S57N 
mutations may create new, solvent-mediated contacts between the PA and the antibody 
(Figure 3.10, right and bottom). The side chains themselves are too far from PA in the 
structure to make direct contacts.  
 
 
Figure 3.10. Structural analysis of the key mutations converting the MAAb to the inferred 
antibody I8. Structures are colored as in Figure 3.9. 
 
H-A50G
H-S57N
H-A102V
H-Y107N
H-A102V
H-A50G
H-S57N
H-Y107N
H-A50G
H-A102V
H-35I
UCA
H-S35I
H-G99A
L-Y94F
I24
I5
CDR-H3
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Following this, a single mutation L-S95P produces sequence I7 (Figure 3.11). The residue 
at L-95 is found in a cis conformation in all structures, which is unfavorable for amino 
acids except proline which has nearly equivalent energies for both trans and cis 
configurations. Having a proline in this location can be predicted to lower the ground state 
and bound state energies of the antibody, and increase stability and affinity. Interestingly, 
this mutation does not occur on other branches of the phylogenetic tree. 
  
 
Figure 3.11. Structural analysis of the key mutation converting I8 to I7. Structures are colored 
as in Figure 3.9. 
 
Subsequently, two mutations occur in the heavy chain, namely H-I35M and H-A99G 
(Figure 3.12). The 35th residue tweaks the hydrophobic pocket between the H1 and H2 
loops that the H-102 fits in, stabilizing the H3 loop in a more optimal position to interact 
with PA. The H-A99G mutation reverts the 99th residue back to the UCA sequence. Unlike 
the UCA, this residue is not in a backbone conformation unique to a glycine residue in the 
HAAb structure. In this case, the smaller glycine side chain would allow for a more 
compact H3 loop folding.  
L-S95P
I5
H-A50G
H-S57N
H-A102V
H-Y107N
UCA
H-S35I
H-G99A
L-Y94F
I24
L-S95P
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Figure 3.12. Structural analysis of the key mutation converting I7 to I6. Structures are 
colored as in Figure 3.9. 
 
The final step in the maturation of this branch involves eight amino acid mutations, seven 
in the heavy chain and one in the light chain. Several of the mutated residues are solvent 
exposed, such as L-T85S, H-G10D, H-S85T, and H-V93I. Individually, these mutations 
do not seem to contribute to the increase in affinity or specificity for the antigen. This 
however does not rule out the possibility of the mutations contributing to affinity or 
specificity in a collective manner or having a role in ensuring stability. There are some key 
mutations that might optimize the folding of the H3 loop to the structure observed in the 
mature antibody. H-V102I adds a larger, more hydrophobic side chain that would pack 
better in the pocket formed by H-M35 and H-G50 and increase contact to PA (Figure 3.13, 
upper right). The H-K98Q mutation disrupts a salt bridge between the residues H-K98 and 
H-D106 by replacing a positively-charged residue with a non-charged residue. In the 
MAAb, this salt bridge stabilizes the carboxy- and amino-terminal ends of the H3 loop 
(Figure 3.13, upper left). Breaking this bond enables the loop to adopt the conformation 
observed in mature antibody in combination with the H-A99G mutation from the previous 
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step. This new conformation allows the formation of a salt bridge with PA-R178. 
 
Figure 3.13. Structural analysis of the key mutation converting I6 to mature antibody. 
Structures are colored as in Figure 3.9. 
 
3.3.4 As a result of affinity maturation, the light chain CDR loops move away from the 
heavy chain 
Overall, the changes to the H3 loop and the residues it packs against affect the variable 
domain orientations (Figure 3.14). The mutations discussed above narrow the H3 loop at 
its termini and fold the end of the loop back against the core beta sheet. With H3 loop 
adopting this conformation, the L chain CDR loops move away from the heavy chain by 
about 2.5 Å. This creates a larger binding surface for the antigen to bind to and better 
position the side chains to interact. The UCA-PA and MAAb-PA complexes are inferred 
from structural alignment, which should be close enough to the real complex structures for 
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the following analyses. We also calculated the buried surface areas and shape 
complementarity between the antibody molecules and the antigen (Table 3.3) (59).  
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Superimposition of MAAb and HAAb where the light chain is shifted away 
from the heavy chain in the HAAb. Structures are colored as in Figure 3.9. 
 
Buried surface area (BSA) is a metric showing the area that becomes inaccessible to the 
solvent upon interface formation. The total buried surface areas show an increase from the 
UCA towards the mature antibody, indicating better contact with the PA antigen. The same 
pattern is observed for the heavy chain BSA. The light chain BSA shows a slight decrease 
from the UCA to the MAAb, but increases for the mature antibody. The shape 
complementarity between the light chain and PA improves all the way from the UCA to 
the HAAb, while the complementarity between the heavy chain and PA first decreases and 
then increases. We observe a significant improvement in the SC between the UCA and the 
Light	Chain	CDRs CDR-H3
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HAAb, as would be expected if the binding mechanism shifts from induced 
fit/conformational selection more towards lock-and-key. Best shape complementarity 
between the heavy and light chains is obtained for the MAAb rather than the HAAb. The 
shift between the heavy and light chains in the HAAb might have resulted in a lower SC 
score. 
 
 
Table 3.3. Buried surface area and shape complementarity characteristics between the 
antibodies and the PA. The values were calculated with the jsPISA server and the SC program of 
CCP4, respectively. 
 
The B-factors in a crystallographic model are a measure of the uncertainty of the positions 
of the atoms. The B-factors are commonly used to infer dynamic information; however, 
they can only provide indirect information, which are affected not only by atomic 
fluctuations but also various factors such as crystal packing, lattice defects, rigid-body 
UCA-PA Medium	Affinity	Ab-PA Mature	Ab-PA
ΔBSAT (Å2) 1497.6 1650.2 1771.6
ΔBSAH (Å2) 684.9 843.5 928.7
ΔBSAL (Å2) 812.7 806.7 842.9
UCA Medium	Affinity	Ab Mature	Ab
VH	&	PA 0.604 0.385 0.694
VL	&	PA 0.384 0.520 0.749
VH	&	VL 0.707 0.737 0.726
MAAb
M Ab
HAAb
HAAb
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motions, and occupancy levels (69, 70). These factors might add too much noise to the B-
factors to provide meaningful conclusions. In addition, a recent molecular dynamics study 
showed that refined B-factors are underestimated in crystal structures by nearly 70% on 
average, with this deviation nearing 85% for B-factors between 10-60Å (71). Our three 
antibodies have different average B-factor values which might be due to any or all of the 
factors above. As a result, we did not draw conclusions about dynamics based on B-factors 
as these conclusions might be misleading.  
 
3.3.5 The crystal structures suggest a lock-and-key binding mode for the HAAb, and 
induced fit/conformational selection binding mode for the earlier antibodies 
The first three mutations result in about a 25-fold increase in the affinity of the antibody. 
The L-Y94F mutation and the two heavy chain mutations that stabilize the H3 loop in the 
conformation observed in the MAAb start the affinity maturation process by an initial 
optimization of the antibody-antigen interface. The next twelve mutations, that increases 
the affinity a further 400-fold, refine the CDR loops to move away from an induced 
fit/conformational selection mechanism to a lock-and-key mechanism, where the mature 
unliganded and liganded antibodies have nearly identical structures (Figure 3.15). The root-
mean-square deviation (RMSD) of the alpha-carbons of the H3 loop of the HAAb is 0.19 
Å, supporting a lock-and-key binding mechanism.  
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Figure 3.15. Superimposition of the unliganded CDR-H3 loops onto the liganded (bordeaux) 
CDR-H3 loop of the HAAb.  
  
3.4 Discussion. 
Previous studies of likely affinity maturation pathways either relied on murine antibodies 
against haptens or model protein antigens, or focused onto broadly-neutralizing antibodies 
against viral antigens. Collectively, these studies showed several mechanisms in play 
during affinity maturation, be it the formation of additional bonds, preorganization and 
fine-tuning of the paratope for improved shape complementarity, increased burial of apolar 
surfaces or a combination of them.  
Here, we studied affinity maturation in a human subject responding to anthrax vaccine 
adsorbed and analyzed multiple stages of the maturation pathway. We determined the 2.39-
2.61 Å resolution crystal structures of three antibodies representing three points along the 
affinity maturation pathway, providing information about the antibody conformations 
(Figure 3.5) as well as key contacts with the PA antigen (Figure 3.7). Our aim was to 
correlate the structural information with the mutational data to follow the evolution of key 
RMSD of the α-carbons of CDR-H3: 
0.19 Å
UCA CDR-H3 MAAb CDR-H3 HAAb CDR-H3
RMSD of the α-carbons of CDR-H3: 
1.38 Å
RMSD of the α-carbons of CDR-H3: 
4.54 Å
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structural features encoded in the antibodies by specific mutations and elucidate the 
mechanisms by which affinity and specificity are improved during the maturation process. 
We mapped the evolutionary information from amino acid sequencing onto the crystal 
structures, and proposed a role for many of the observed mutations. While some key 
changes are to residues that directly contact the antigen, notably the residue L-94, majority 
of the mutations that occur between the UCA and the mature antibody are not contact 
residues. Most of the mutations are to key structural positions in the CDR loops, in 
particular the CDR-H3 loop that seem to optimize the CDR loop conformation for better 
contacting the PA antigen. These mutations also move the binding away from an induced 
fit/conformational selection mechanism in the UCA and MAAb antibody to a more rigidly 
lock-and-key mechanism in the HAAb. As emphasized in the introduction, this shift to 
lock-and-key is not to suggest total rigidification of the HAAb and motions would be still 
expected from both partners. It indicates that the bound conformation becomes most  
In summary, mutations to predominantly non-contact residues appear to have increased the 
shape complementarity between the antigen and the antibody via the preconfiguration of 
the H3 loop and the shift in the heavy and light chains, and maximized the non-covalent 
interactions between the two molecules.
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CHAPTER FOUR: THERMODYNAMIC EVOLUTION DURING AFFINITY 
MATURATION 
 
4.1 Introduction. 
A crucial part of the immune system involves antibody binding to its antigen. The antigen-
antibody binding involves noncovalent interactions, including electrostatic and van der 
Waals forces, hydrogen bonds and hydrophobic effects. The nature of molecular 
recognition between an antigen and an antibody is controlled by the energetics of their 
interaction, which determines the particular antibody’s mechanism of interaction. 
Isothermal titration calorimetry (ITC) is a label-free, solution-based technique that 
measures the binding thermodynamics, providing a breakdown of the contributions to the 
free energy of binding. The Gibbs free energy is a combination of enthalpy, ΔH, and 
entropy, ΔS. ITC is capable of measuring enthalpy of the binding directly, and estimating 
the association constant, KA and stoichiometry, n (Figure 4.1). From KA, the Gibbs free 
energy is calculated as ΔGbind = –R*T*ln(KA), where T is the absolute temperature, 
and R = 1.98 cal mol–1 K–1 is the universal gas constant. The entropy, ΔSbind, is calculated 
from ΔG =ΔH – TΔS. 
Enthalpy change is the net heat change associated with the formation and breaking of non-
covalent bonds. Entropy can be defined as a measurement of the degeneracy of a system, 
the multiplicity of ways in which a system can be found with a particular energy. At higher 
energy states, there would be more ways of distributing this energy to reach the same total; 
and the molecules can be found in various conformational states. Hence, when there are  
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Figure 4.1. An example ITC raw data and the binding isotherm. The binding isotherm is 
obtained through integration of each peak in the raw data, which is then plotted as a function of 
molar ratio of titrant/titrand. Figure taken from the “Introduction to Microcalorimetry” presentation 
of Malvern Instruments, 2013. 
 
restrictions on the conformational, rotational and translational degrees of freedom, there 
would be less ways the system can be in, which would be reflected as “increased order” or 
lower entropy. 
Several studies characterizing antibody-antigen binding via ITC have shown that the 
binding process can be enthalpically and/or entropically driven. Some antibody-antigen 
interactions appear to be primarily enthalpy driven, realizing the binding via forming van 
der Waals interactions, hydrogen bonds and electrostatic interactions (72). The positive 
enthalpic components must overcome the entropic penalties such as inherent loss of 
flexibility (rotational, translational and conformational) upon binding the partner, the 
inherent entropy loss from two parts becoming one part, and/or desolvation penalty at the 
binding surface. When two molecules interact via the lock-and-key binding mechanism, 
the unbound molecules are already in the optimal, bound conformation and hence do not 
Raw data
Reported data
(ΔH)
Mechanism (KA) Binding
(n) stoichiometry
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undergo a loss of conformational entropy upon binding (32). Other interactions are mainly 
entropy driven, decreasing exposed hydrophobic areas upon binding and releasing ordered 
waters at the interaction surface into the bulk solvent, improving entropy through what is 
termed as the “hydrophobic effect” (73).  
 
4.1.1 Role of enthalpic and entropic factors during affinity maturation: 
Earlier studies done with both antibody-hapten and antibody-protein antigen pairs 
suggested that entropy was the predominant player in affinity maturation (72). (4-hydroxy-
3-nitrophenyl)acetyl-antibodies which were considered to belong to the same clone were 
shown to increase their affinities by improvements in entropy with no changes in enthalpy 
(43). The mutations contributing to affinity maturation were mainly located in the 
framework regions and suggested to be responsible for changing the conformation of the 
antigen-binding site or the VH-VL stability, shifting the binding mechanism from induced 
fit to more of a lock-and-key binding. A mutation-induced change in the binding 
mechanism has been observed in other studies as well. An anti-N-methyl-mesoporphyrin 
unmutated ancestor antibody was found to bind to another antigen, jeffamine, with similar 
affinity as it binds to its cognate antigen (74). The affinity matured antibody, however, 
could only bind to the cognate antigen and not to jeffamine. Crystal structures indicated a 
lock-and-key binding mode for the mature antibody that sterically inhibited the binding to 
jeffamine, while the unmutated ancestor antibody appeared very flexible with an inducible 
fit that accommodated both antigens. Through computational modelling, this entropic 
improvement in binding was attributed to the loss of flexibility in the CDR-H3 loop during 
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affinity maturation (75).  
With more structures of antibodies before and after affinity maturation being solved, 
examples of enthalpic contribution have also been observed. A mature nitrophenyl 
phosphonate antibody demonstrated a 30,000-fold increased affinity compared to the 
precursor antibody through 9 mutations, none of which contacted the antigen (32). While 
the crystal structures showed a stabilization in the paratope of the mature antibody, again 
indicating a shift from induced fit to lock-and-key, additional hydrogen bonds, salt bridges 
and aromatic interactions formed by the mature antibody with the hapten were also noted. 
Mutations in the light chain were suggested to rearrange the sidechains to modulate the 
affinity, while heavy chain mutations reorganized both the backbone and the sidechains. 
Another antibody-hapten study structurally compared affinity matured and unmutated 
ancestor antibodies against a methylphosphonate derivative (76). The affinity matured 
antibody had more electrostatic and hydrophobic interactions with the hapten compared to 
the unmutated ancestor and was shown to bind the hapten in a lock-and-key fashion. In an 
anti-testosterone antibody developed by optimization of the CDR residues, a 40-fold 
increase in affinity was observed as a result of 20 mutations (77). They determined one 
significant mutation in the heavy chain which allowed closer contact with the antigen 
through providing more space. The important light chain mutations had no direct contact 
with the antigen but contributed to the affinity increase by rearranging the conformation of 
CDR-L1 loop, leading to an overall fine-tuning of the binding site. Another study compared 
mutant hen egg lysozyme specific single-chain variable domain fragment (Fv) antibodies 
in terms of structure and thermodynamics (78). No structural changes were observed as a 
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result of mutations; however, the mutated residues resulted in the loss of hydrogen bonds 
with the surface waters which were reflected as increases in both negative enthalpic and 
entropic values. These results indicated that hydrogen bonding via surface waters 
enthalpically contributed to the antigen-antibody interactions and structurally stabilized the 
complex. 
These studies demonstrate that affinity maturation can be achieved via enthalpic 
improvements, entropic improvements or a combination of both. In this part of the 
dissertation, we characterize the thermodynamics of the three anti-anthrax antibodies and 
delineate the changes in the enthalpic and entropic components of binding during affinity 
maturation. 
 
4.2 Experimental Protocol. 
ITC experiments were performed using a VP-ITC instrument from Microcal 
(Northampton, MA). The antibody samples and the antigen were dialyzed in the titration 
buffer (10 mM HEPES, 150 mM NaCl at pH 7.5) at 4°C overnight with stirring. Injections 
of 10-20 µl of antigen solution were added from a computer-controlled microsyringe at an 
interval of 3 minutes into the sample solution of Fab antibody (cell volume = 1.43 ml) with 
stirring at 307 RPM at 27°C. As one of the samples did not give observable heat peaks at 
room temperature, all samples were characterized at 27°C for comparison purposes. The 
concentration range of the antibodies was 1–5 µM, and the antigen concentration was 10–
100 µM, as measured by NanoDrop (Thermo Fisher). The AFFINImeter software 
(www.affinimeter.com) subtracted the heat of dilution from the total heat and integrated 
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the peaks to obtain the binding isotherm (red lines), which was then fitted to a theoretical 
titration curve of the 1-site binding model to estimate the binding enthalpy, ΔHbind 
(kcal/mol) and the equilibrium association constant, KA (M-1) (Figure 4.1). The 
stoichiometry was fixed to n=1 during fitting, as fixing n has been shown to yield less 
uncertainty in the binding enthalpy and free energy than allowing it to float (79). For the 
HAAb, the KD value determined from SPR was used for estimation of the Gibbs Free 
Energy, as the titration curve becomes too steep for accurate estimation by the ITC when 
an interaction has a single-digit nanomolar or tighter affinity. The uncertainty estimation 
of the single points in the binding isotherm relies on the NITPIC algorithm, which has been 
shown to have improved detection limits for high-affinity or low-enthalpy binding 
reactions, and significantly higher precision of the derived thermodynamic parameters 
compared to other available methods (80). 
The distance between the minimal and maximal heat formation represent the change in 
enthalpy. n is the molar ratio at the transition midpoint of the sigmoidal curve, reflecting 
stoichiometry. The slope at the transition midpoint gives the Ka. The free energy, ΔGbind, 
is calculated from Ka through the equation ΔGbind =–R*T*ln(Ka). The entropy, ΔSbind, is 
calculated from the equation ΔG =ΔH – TΔS, where T is the absolute temperature, and R = 
1.98 cal mol–1 K–1 is the universal gas constant.  
 
4.3 Results. 
Gibbs free energy of binding consists of enthalpic and entropic components, where ITC 
allows direct measurement of the enthalpy of a binding interaction. With this parameter 
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and the free energy of binding known, it is possible to calculate the entropy of binding. 
Here, the three antibodies were titrated with their antigen, PA, to determine the 
thermodynamic components of binding (Figure 4.2). 
All the interactions are enthalpically favorable and entropically disfavored at the measured 
temperature (Figure 4.3). This pattern is common in many protein-protein interactions, 
including several antigen-antibody pairs. The favorable enthalpy demonstrates the 
formation of noncovalent bonds between the antigen and the antibody. The interaction 
between the antigen and the antibody requires the desolvation of the interaction surface, 
losing the solvent-based enthalpic contributions. Hence, the enthalpic gain through 
antigen-antibody binding needs to compensate for this loss through forming new 
interactions. Unfavorable entropy might be stemming from the loss of conformational, 
translational, and rotational freedom upon binding the partner. While the release of the 
surface water molecules during binding contributes to the entropy favorably, the 
unfavorable contributions are greater as observed by the entropy values obtained. 
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Figure 4.2. ITC thermograms with curves fitting the data are displayed for interactions between PA and the three antibodies. The 
thermodynamic parameters obtained from fitting are provided in boxes at the lower right corner.  
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Figure 4.3. Summary of thermodynamic parameters determined from ITC of the three 
antibodies interacting with the PA antigen.  
 
The affinities obtained from ITC are comparable to the values obtained by surface plasmon 
resonance. The affinity increase is achieved in a stepwise manner. In the first step from the 
UCA to the MAAb, an enthalpic improvement is observed, indicating optimization of the 
noncovalent interactions through adopting a more optimal conformation for contacting the 
antigen as suggested by the crystal structures. The second step from the MAAb to the 
HAAb predominantly involves entropic improvement by which the advantageous 
conformation made accessible in the first stage is made more dominant through the 
narrowing of effectively accessible conformations, which also allows better bond 
formation with the antigen as reflected by the enthalpic improvement. The affinity increase 
in this step is several folds higher than the increase in the first step. 
  
-1.60E+04
-1.20E+04
-8.00E+03
-4.00E+03
0.00E+00
4.00E+03
8.00E+03
UCA
Medium
Affinity Ab Mature Ab
ca
l/m
ol
ΔH
-TΔS
ΔG
Favorable
Unfavorable
		
67 
4.4 Correlation of structural data with thermodynamic data. 
From the UCA to MAAb, an increase in favorable enthalpy and a slight increase in 
unfavorable entropy, which might be insignificant considering the uncertainty involved in 
the measurements, are observed. Y94 in the light chain forms van der Waals interactions 
with PA-P513. However, Y94 is too close to PA-T516, forming a steric clash (Figure 4.4). 
When this residue mutates into phenylalanine in MAAb, the antibody and the antigen can 
come closer and interact better, providing an explanation for the enthalpic increase for the 
MAAb. This L-Y94F mutation is incorporated very early in the phylogenetic tree and is 
maintained throughout the maturation process in all sequences. 
 
 
Figure 4.4. Steric clash between UCA and PA. The disks, drawn by Pymol’s “show bumps” 
script, indicate significant overlap in the van der Waals radii of the interaction atoms. The distance 
between the atoms is 1.4Å, while the van der Waals radii of the atoms are 1.7Å and 1.5Å where 
the overlap can be calculated as overlapij = rVDWi + rVDWj – dij – allowanceij, dij referring to the 
distance between the atoms and allowanceij referring to hydrogen bond allowance when the pair 
consists of a donor and an acceptor. 
 
L-Y94
PA-T516
distance = 1.4Å 
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From the MAAb to HAAb, we observe an increase in favorable enthalpy and a more 
significant decrease in unfavorable entropy. The increase in enthalpy might be due to the 
salt bridge formation between H-D106 and PA-R178, as well as solvent-mediated 
interactions of H-57N with PA. Interestingly, salt bridge formation has also been suggested 
to make an entropic contribution to the protein antigen-antibody interaction via reduction 
of entropy loss as a result of dehydration and structural changes (81). There are also several 
surface-exposed residues that individually do not seem to contribute to affinity but might 
do so collectively and contribute to the increase in enthalpy. 
The light chain’s 95th residue is in a cis conformation in all three antibodies, which is least 
unfavorable for proline compared to other amino acids. Having a proline in this location 
can be predicted to lower the ground state and bound state energies of the antibody; and 
increase stability and affinity. Hence, a contribution to the decrease in the unfavorable 
entropy from the MAAb to the HAAb can be expected by having a proline in this location 
in the mature antibody. In addition, the highly similar conformations of the unliganded and 
liganded HAAb suggest a conformational restriction in this Ab structure compared to the 
earlier antibodies, which can translate as a decrease in the loss of configurational entropy 
upon binding, hence the more favorable entropy.  
 
4.5 Discussion: 
This study demonstrates that affinity maturation of these three antibodies involves distinct 
energetic changes at various maturation stages. We correlated the energetics with structural 
data, providing complementary insight into the nature of changes giving rise to these 
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thermodynamic parameters. We suggest that mutations in both the heavy and light chains 
have entropic and enthalpic contributions to binding. The first step from the UCA to the 
MAAb involves enthalpic improvement, indicating optimization of the noncovalent 
interactions between the antibody and its antigen, which is due, in part to the removal of 
their steric clashes. The second step from the MAAb to the HAAb involves predominantly 
entropic improvement, pointing out to a shift in the binding mechanism from 
conformational selection/induced fit towards lock-and-key along with increased stability 
in the antibody. The optimal structure adopted by the HAAb improves surface 
complementarity and allows better contacts with the antigen, as demonstrated by the 
enthalpic improvement in this step.  
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CHAPTER FIVE: DYNAMIC EVOLUTION DURING AFFINITY 
MATURATION 
 
5.1. Introduction. 
Structural dynamics and flexibility of both the paratope and its periphery impact the affinity 
and specificity of antigen-antibody interactions (29, 82). Therefore, it is important to 
characterize the dynamic changes during affinity maturation. While crystal structures 
provide valuable information about structural changes during affinity maturation, they are 
static images that are time- and ensemble-averaged. They can only provide indirect 
dynamic information through B-factors, which are affected not only by atomic fluctuations 
but also various factors such as crystal contacts, lattice defects, rigid-body motions, and 
occupancy levels (69, 70). In addition, a recent molecular dynamics study showed that 
refined B-factors are underestimated in crystal structures by nearly 70% on average, with 
this deviation nearing 85% for B-factors between 10-60Å (71). As a result, to characterize 
the dynamics with direct tools rather than indirect methods is preferable. Hydrogen-
Deuterium Exchange Mass Spectrometry (HDX-MS) is one such tool that can provide 
dynamic and conformational information on proteins in solution.  
 
5.1.1. The theory and mechanisms of HDX 
When a protein is incubated in deuterium oxide (D2O), its labile hydrogen atoms exchange 
with deuterium. Amine, carboxyl and hydroxyl group hydrogens of amino acid side chains 
exchange with deuterium instantaneously, but they readily revert to hydrogen. The 
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hydrogens covalently attached to the backbone and side chain carbons do not exchange. 
The backbone amide hydrogens on the other hand exchange into deuterium in measurable 
times, ranging from hundreds of milliseconds to years (83). As deuterium is heavier than 
hydrogen, this shift in mass can be detected by mass spectrometry. For subsequent mass 
spectrometric analysis, protein samples are quenched at specific incubation time points and 
digested with a protease under conditions to retain the labeling information and minimize 
back-exchange. The level of deuterium uptake is then quantitatively determined for each 
peptide. The hydrogen-deuterium exchange rate is a function of both protein structure and 
solvent accessibility (84).  
The general hydrogen exchange mechanism (Figure 5.1) assumes a pre-equilibrium 
between an exchange-incompetent, closed state and an exchange-competent, open state. In 
the closed state, the hydrogen is protected from exchange via hydrogen-bonding or 
exclusion from the solvent (85). Regions like loops that are unstructured and solvent-
exposed can exchange very rapidly. On the other hand, regions that are rigid, involved in 
hydrogen bonding networks, and/or buried inside the protein exchange more slowly, only 
when local or global fluctuations disrupt their interactions with neighboring groups and 
expose the region to solvent. 
 
 
 
		
72 
 
Figure 5.1. Linderstrøm–Lang kinetic model for exchange of protected hydrogens. kop and kcl 
are structural opening and closing rates, while kex is the intrinsic exchange rate specific for the 
exposed amide hydrogen. 
 
The HX rate obtained from the kinetic model is kHX = kop kex / (kop+kcl+kex) with two 
assumptions made to uncouple the conformational and intrinsic parameters of the process. 
The first assumption is the pH independency of the conformational fluctuations, and the 
second is an equal rate of exchange for individual amides in the open state versus model 
peptides with identical neighboring side chains (85). There are two HDX regimes, EX1 
and EX2. The majority of the proteins under native conditions follow the EX2 limit, where 
kex << kcl, indicating that the reclosing of transient structural openings is faster than the 
intrinsic exchange rate (86). This regime is characterized by a gradual time-dependent 
increase in the average mass of individual peptides. The less common EX1 regime can be 
induced by the extremes of pH or the help of denaturants, and arises when a portion of the 
molecule undergoes a cooperative unfolding event such that several residues are exposed 
to deuterium simultaneously. The exposed residues exchange their backbone hydrogens 
into deuterium before that region is folded back, where kcl << kex. 
Over the broadest time window, HDX kinetics is roughly biphasic. There is a fast phase 
arising from unstructured amides and a slow phase arising from structured amides. While 
all amides contribute to the exchange at every timepoint, the first several seconds of 
Closed	 Open Exchange
kexkop
kcl
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exchange are dominated by unstructured amides and can be considered to be solely local 
unfolding with negligible contribution from subglobal or global unfolding (87, 88). We 
consider the final timepoint at 3 hours to be an outcome of predominantly global unfolding 
which transiently produces random-chain conformations that fully expose main-chain 
amides and release side-chain constraints. Measurements recorded between these temporal 
limits can be considered a combination of both modes. 
The determinants in local unfolding, which determine the exchange of many protein 
hydrogens, are still obscure despite attempts of predictive calculations to correlate HDX 
rates with static and structural factors. Establishing correlations with the determinants and 
deuterium uptake is non-trivial as the local fluctuations that determine the HDX behavior 
are rare, with populations from 10−1 to 10−10 relative to the native state and with timescales 
from milliseconds to months. In addition, some local fluctuations only expose one 
hydrogen at a time, while others expose several hydrogens simultaneously (89). While the 
exchange mechanisms are understood better than 50 years ago thanks to a multitude of 
computer simulations and detailed experiments, explaining the changes in deuterium 
uptake structurally is still very complicated (90-92). As a result, most HDX data are being 
interpreted qualitatively.  
 
5.1.2 Structural Factors Affecting the Exchange Rate 
Until recently, it was thought that solvent proximity increased the rate of exchange, with 
buried proteins subject to lower exchange rates. However, various studies observed that 
residues at the protein surface would have extremely slow exchange, while some interior 
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residues had unexpectedly high exchange rates (93-95). To explain these phenomena, 
several factors have been suggested to play a role. For surface residues, relative solvent 
exposure and electrostatic field were offered as potential factors (95-97). For buried 
hydrogens, solvent penetration into the protein, burial depth, hydrogen bonding, local 
packing density and local, transient unfolding reactions were considered (96, 98, 99). 
The Englander group performed a detailed investigation regarding the roles of these factors 
in exchange rate, and reported that hydrogen bonding was the most important factor in 
determining the exchange rates (91, 93). Surface residues that were hydrogen bonded to 
the backbone carbonyls or side chains of other residues or even the solvent itself had an 
average 10-fold slower exchange rates compared to amides in unstructured model peptides 
(93). Hydrogen bonds can sterically block normal exchange chemistry, and hence the 
interacting residues need to be separated to break the bond and allow bonding to HDX 
catalysts (100).  
One of the interesting outcomes from the Englander’s group study is that individual 
backbone amides can exchange at rates totally different from those of immediate 
neighboring residues, which is attributed to a crankshaft motion of the specific residue; 
making peptide-based interpretations more complicated. Another interesting result is that 
while hydrogen bond acceptor type was not observed to affect exchange rates, there was 
evidence of a collective solvent exposure behavior for the residues connected to one 
another. We observe a similar pattern in our antibody samples, which we characterized 
with hydrogen exchange mass spectrometry over 8 timepoints to observe the dynamic 
changes occurring in various regions of the antibodies during affinity maturation. 
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5.2. Experimental Protocol. 
The HDX workflow is shown in Figure 5.2. Basically, buffered protein solutions at 
physiological pH are diluted with the identical buffer containing 99.9% D2O. The exchange 
reaction proceeds for various amounts of time and is quenched by lowering the pH and the 
temperature to minimize back-exchange. Deuterated, quenched protein is then digested 
with an acid protease prior to liquid chromatography and mass analysis. The mass spectra 
are analyzed, the uptake of deuterium over time is determined for each peptide.  
 
 
Figure 5.2. Workflow of HDX-MS.  
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into a Waters HDX nanoAcquity UPLC (Waters, Milford, MA) with in-line pepsin 
digestion (Waters Enzymate BEH pepsin column). Peptic fragments were trapped on an 
Acquity UPLC BEH C18 peptide trap and separated on an Acquity UPLC BEH C18 
column. An 18 min, 5% to 95% acetonitrile (0.1% formic acid) gradient was used to elute 
peptides directly into a Waters Synapt G2 mass spectrometer (Waters, Milford, MA). MSE 
data were acquired with a 80 V ramp trap CE for high energy acquisition of product ions 
as well as continuous lock mass (Leu-Enk) for mass accuracy correction. Peptides were 
identified using the ProteinLynx Global Server 3.0.1 (PLGS) from Waters. Further filtering 
of 0.1 fragments per residues, minimum intensity of 1000 and file threshold of 2 was 
applied in DynamX 3.0. 
For each construct, the HD exchange reactions were performed as follows: 0.9 mg/ml 
samples in 50 mM HEPES, 100 mM NaCl pH 7.0 were diluted 1:20 with 50 mM HEPES, 
100 mM NaCl, 99.9% D2O (Cambridge Isotope Laboratories, MA), pD 6.6 at room 
temperature. Labeling reactions were performed at 25°C for various times (10 s, 30 s, 
1 min, 5 min, 10 min, 30 min, 1 hr, 3hrs), followed by the addition of equal volume of ice 
cold quenching buffer and incubating the samples for 5 minutes (200 mM Phosphate 
buffer, 0.5 M TCEP, 4 M Guanidine-HCl, pH 2.3). At acidic pH, around pH 2.3-2.5, the 
exchange rate decreases 103-104 fold compared to pH 7 (101). An additional 10-fold 
reduction is achieved through decreasing the temperature from 25°C to 0°C. Hence, the 
quench conditions are chosen appropriately to minimize back-exchange during the 
analysis.  
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All deuteration time points and controls were acquired in duplicates or triplicates, with the 
exception of 180 minutes incubation which was measured once. Fully deuterated samples 
were obtained by first digesting the antibody and collecting the peptides from the pepsin 
digestion column, and then labelling the peptides at the same conditions as before for 4 
hours. The deuterium uptake by the identified peptides through increasing deuteration time 
was determined using the Waters’ DynamX 3.0 software. The uptake was corrected for 
back-exchange using the following equation (102): 
 
 
 
where Dcorr,t denotes the corrected deuterium uptake at time t; Dt is the measured deuterium 
uptake; mavg,100% and mavg,t0 are the average mass of the fully deuterated peptide and the 
average mass of the peptide at time t0; nlabile is the number of exchangeable H-atoms for 
that peptide. 
To compare flexibility and dynamics among different parts of the protein, the 
normalization of the deuterium uptake levels after back-exchange correction was done 
using the following equation: 
 
 
 
Dcorr,t =
mavg,100%-mavg,t0
nlabile
Dt x
D%	=
Dcorr,t
N
x100%
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5.3 Results. 
We identified peptic fragments covering over 93% of the heavy and light chains of the 
three antibodies (Figure 5.3). While nearly all regions of the antibodies could be monitored 
with HDX-MS, the antibodies did not share identical pepsin digestion patterns due to the 
mutations in variable regions which hindered a complete comparison of deuterium uptake 
between the three antibodies.  
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Heavy	chain
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Figure 5.3 Coverage Maps of the UCA, MAAb and HAAb. 
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Deuterium uptake for all peptides identified under the experimental HDX conditions 
exhibited a single isotopic distribution that increased in mass over time, displaying the EX2 
kinetic behavior. The differences in the dynamics are represented in various formats, 
ranging from vertical heatmaps (Figure 5.4) to structural heatmap summaries (Figure 5.5) 
to difference heatmaps (Figure 5.6). Overall, the heavy chain becomes more protected 
during affinity maturation, while the dynamics of the light chain is not affected 
significantly, with the exception of CDR-L1 which shows slight protection with affinity 
maturation.  
 
Figure 5.4. Vertical-format deuterium uptake heatmaps of the UCA, MAAb and HAAb at 
different timepoints. The CDR regions are labelled on the heatmaps. Missing coverage is denoted 
in gray. 
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Figure 5.5. Deuterium uptake heatmaps for UCA (left), MAAb (middle), HAAb (right) 
mapped onto the HAAb structure. The colors indicate % deuteration for antibody peptides after 
10 seconds of incubation in D2O. Black indicates missing coverage on the difference heatmap due 
to missing peptides.  
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Figure 5.6. Difference heatmaps of UCA-MAAb and MAAb-HAAb mapped onto the HAAb 
structure. a) Difference heatmap for UCA-MAAb indicate regions that are more disordered in the 
UCA relative to MAAb (blue), regions similarly ordered in both antibodies (white), and regions 
that are more ordered in the UCA relative to MAAb (red). b) Difference heatmap for MAAb-HAAb 
indicate regions that are more disordered in the MAAb relative to HAAb (blue), regions similarly 
ordered in both antibodies (white), and regions that are more ordered in the MAAb relative to 
HAAb (red). Black indicates missing coverage on the difference heatmap due to missing peptides. 
Constant regions grayed out. Colors mapped onto the HAAb structure indicate % deuteration for 
antibody peptides after 10 seconds of incubation in D2O. 
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protected in the mature antibody, indicating higher stability in these regions. We also 
analyzed the hydrogen bonding of the amides with other residues as well as 
crystallographically refined water. For the peptides 94-105 and 106-113, we observed 
extensive hydrogen bonding – a total of 8 H-bonds - to other residues and water molecules, 
with hydrogen bonds also formed where the two peptides interacted with each other to 
stabilize the beta sheets and the connecting residues in the loop also formed hydrogen 
bonds. These hydrogen bonds can explain the increased stability for these regions of the 
mature antibody. The UCA and the MAAb had a total of 6 hydrogen bonds in these two 
peptide regions. The higher deuterium uptake in the MAAb might seem surprising 
considering that it has a salt bridge in its CDR-H3 loop and yet still demonstrates higher 
dynamics than the mature antibody. However, salt bridges at protein surface are known to 
be only marginally stabilizing (103), and in some cases have even been shown to be 
destabilizing (104). As the 94-105 and 106-113 peptides involve 3 residues that interact 
with the antigen, if they are fluctuating less (and hence are more stable), this may allow 
longer-lasting interactions with the antigen, enabling higher binding affinity.  
Interestingly, peptide 24-32 that spans the CDR-H1 loop has higher deuterium uptake in 
the HAAb, followed by the MAAb and the UCA for the earlier timepoints. After 1 minute 
incubation, the curves overlap. This indicates that the local unfolding behavior of this 
region is different for the three antibodies, while the global unfolding is similar. This region 
interacts with the N-terminus of the protein, which is generally very flexible in most 
proteins. Hydrogen bonding with the N-terminus therefore would be more transient than 
an interaction with a more stable region, allowing the CDR-H1 region to expose its residues 
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to the solvent more often. 
The peptide 52-68 that spans the CDR-H2 forms several contacts with the FW3 region. 
This peptide region is more protected in the UCA compared to the other antibodies, as is 
the peptide 84-93 with which it interacts. While the MAAb 84-92 peptide overlaps with 
the UCA peptide at later timepoints, the fast dynamics indicating local unfolding is again 
lower in the UCA compared to the MAAb.  
Looking at the light chain, we see that the majority of the regions had similar deuterium 
uptakes, especially between the UCA and the MAAb. The CDR-L1 region becomes more 
protected in the HAAb. Interestingly, the peptide 55-72 which spans the C-terminus end of 
the CDR-L2 and half of the FW3 has a lower deuterium uptake in the MAAb that returns 
to the baseline in the HAAb.  
While some peptides spanning the constant region show different uptake levels among the 
three antibodies, the majority of the peptides uptake similar levels of deuterium in all three. 
Two constant chain peptides in the light chain show differential deuterium uptake. The 
UCA is more stable in one of the constant region peptides that is close to the C-terminus 
of the protein.  
In summary, affinity maturation increases the protection of the CDR-H3 and FW-4 regions 
in the HAAb along with the FW-1, FW-2 and N-terminus FW-3 regions; whereas the CDR-
H1 and CDR-H2 regions, as well as the C-terminus FW-3, become less protected. These 
results demonstrate the stabilization of the majority of the paratope periphery with a key 
paratope region in the heavy chain, while two other paratope regions become less 
stabilized. The light chain appears relatively unaffected, with slight protection observed in 
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the CDR-L1.  
Some of the regions that show a change in the uptake levels do not involve any mutations, 
suggesting intra-protein interactions as well as allosteric effects due to the mutations 
accumulated throughout the process.    
 
5.4. Discussion. 
The traditional affinity maturation process of haptens has aimed to improve the affinity and 
specificity to the antigen by optimizing the interacting residues and rigidifying the paratope 
through mutations in the periphery and the paratope itself. Later studies done with a model 
protein as well as with viral antigens showed various mechanisms for antibody maturation 
such as increased burial of apolar residues or increased stability of the sites peripheral to 
the paratope (82).  
In this study, we characterized three antibodies showing a direct lineage relationship to 
determine whether affinity maturation stabilized the paratopes to enable stronger binding 
to the antigen. We indeed observed a stabilization in the CDR-H3 region of the mature 
antibody along with several framework regions, while the other regions were affected in a 
site-specific manner. An alternating pattern of increasing and decreasing protection of the 
regions is observed during affinity maturation. Overall, the heavy chain became more 
stabilized, while the light chain did not exhibit much changes. This can be a result of the 
low number of mutations accumulated in the light chain, where the MAAb acquired one 
mutation in the light chain and the HAAb acquired two mutations in the light chain 
compared to the UCA.  
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These results suggest that both the paratope and the periphery get optimized in these 
antibodies, which is important in the affinity maturation response to complex protein 
antigens, where the bulky antigen needs to be accommodated by the antibody while still 
retaining contact with it. 
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5.5 Percentage Deuterium Uptake Plots. 
 
Figure 5.7. Representative peptides from the heavy chain. Peptide-level comparison of the 
UCA, MAAb and HAAb. 
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Figure 5.8. Heavy chain peptide-level comparison of the UCA with the MAAb. 
 
 
Figure 5.9. Heavy chain peptide-level deuterium uptake comparison of the UCA with the 
HAAb. 
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Figure 5.10. Heavy chain peptide-level deuterium uptake comparison of the MAAb with 
HAAb. 
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Figure 5.11. More peptides from the heavy chain. Peptide-level deuterium uptake comparison 
of the UCA, MAAb and HAAb. 
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Figure 5.12. Peptide-level deuterium uptake comparison of the light chains of the UCA, 
MAAb and HAAb. 
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Figure 5.13. Light chain peptide-level deuterium uptake comparison of the UCA and the 
MAAb. 
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Figure 5.14. Light chain peptide-level deuterium uptake comparison of the UCA and HAAb; 
MAAb and HAAb.
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (5-11)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (36-46)
UCA HAAb
0
20
40
60
80
100
120
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (47-54)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (75-83)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (95-116)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (116-124)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (137-148)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light chain (179-192)
UCA HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light Chain (95-116)
MAAb HAAb
0
20
40
60
80
100
0.167 0.5 1 5 10 30 60 180
De
ut
er
iu
m
 U
pt
ak
e 
(%
)
Time (min)
Light Chain (136-172)
MAAb HAAb
		
94 
CHAPTER SIX: CONCLUDING REMARKS 
 
6.1 Overview. 
In this dissertation, we studied the human antibody affinity maturation in response to 
repeated vaccination. We first measured the affinity of several PA-specific antibodies of 
the largest clones from two donors who were vaccinated with the anthrax vaccine adsorbed 
5 times over a period of 18 months. We then chose three antibodies lying along a single 
clonal branch--the clone’s unmutated common ancestor, a medium affinity antibody 
appearing after second immunization, and a high-affinity antibody appearing after third 
immunization. We characterized these antibodies in terms of their kinetics, structure, 
dynamics and thermodynamics to get a better understanding of how affinity maturation 
results in higher affinity in antibodies. 
 
6.2 Summary of Major Findings. 
In Chapter Two, we measured the on-rates, the off-rates and the affinities of representative 
antibodies from the largest clones of two donors. The key findings in this chapter are: 
- The affinity increases from micromolar to picomolar levels. 
- For both donors, the clones appear to be fully mature after the third immunization, 
regardless of their first appearance. 
- The on- and off-rates appear to be controlled independently from each other during 
the maturation of antibody response. The on-rates start out fast, and do not change 
much during affinity maturation, while the off-rates improve significantly. 
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In Chapter Three, we determined the crystal structures of the three antibodies, providing 
information about the folding of the antibodies as well as critical contacts to the PA antigen. 
The evolutionary information from sequences was mapped to the crystal structures, and we 
proposed a role for many of the observed amino acid sequence changes. The key findings 
in this chapter are: 
- The antigen-binding is mostly conserved in the three antibodies, with the exception 
of the CDR-H3 loop. 
- The epitope consists of the domains 1 and 3 of the PA antigen, while the paratope 
involves all six CDR loops with the majority of the interaction interface comprised 
by the CDR-H3 and CDR-L3 loops. 
- As a result of affinity maturation, the light chain moves away from the heavy chain, 
allowing better contact with the antigen.  
- The binding mechanism shifts from conformational selection/induced fit in the 
UCA/MAAb more towards lock-and-key in the HAAb. 
 
In Chapter Four, we characterized the thermodynamic profiles of the antibodies and how 
the thermodynamic parameters change during affinity maturation. The key findings are: 
- All the interactions are enthalpically favorable and entropically disfavored at the 
measured temperature. 
- The affinity increase is achieved in a stepwise manner. 
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- The first maturation step from the UCA to the MAAb involves enthalpic 
improvement, indicating optimization of the noncovalent interactions between the 
antibody and its antigen, which is due, in part to the removal of their steric clashes. 
- The second maturation step from the MAAb to the HAAb involves predominantly 
entropic improvement, supporting the conclusions drawn from crystal structures 
regarding the change in the binding mechanism. The optimal structure adopted by 
the HAAb improves the contacts and allows new interactions to be formed between 
the antibody and the antigen, as also demonstrated by the improvement in the 
enthalpy. 
 
In Chapter Five, we analyzed how the dynamics of the antibodies change during affinity 
maturation. The key findings are: 
- An alternating pattern of increasing and decreasing protection of the regions is 
observed during affinity maturation, where both the paratope and its periphery get 
optimized in terms of dynamics. 
- The CDR-H3 and the majority of the heavy chain frameworks, with the 
exception of FW3, become less dynamic, while CDR-H1 and CDR-H2 become 
more dynamic. 
- The light chain does not exhibit much changes in dynamics during affinity 
maturation. 
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6.3 Discussion. 
The three antibodies that show a direct lineage relationship exhibit four orders of 
magnitude increase in their affinities, increasing from 1.5 µM affinity of the UCA to 68 
nM affinity of the MAAb to 160 pM affinity of the HAAb. This increase in affinity is 
contributed mainly by a decrease in the off-rates. The crystal structures suggest that the 
earlier two Abs undergo conformational changes upon binding the antigen, while the 
unbound structure of the HAAb is highly similar to the bound HAAb structure with little 
distortion upon binding. The mutations in the HAAb have the net effect of narrowing the 
CDR-H3 loop at its termini and folding the end of the loop back against the core beta sheet. 
This preorganization of the H3 loop makes the unbound loop adopt the bound 
conformation, which might explain the decrease in the unfavorable entropy from the 
MAAb to the HAAb as the configurational entropy loss due to binding can be expected to 
be lower. As a result of the H3 loop adopting this conformation, the light chain CDR loops 
move away from the heavy chain by about 2.5 Å. This creates a larger binding surface for 
the antigen to bind to and better position the side chains to interact.  
Long-range electrostatic interactions have been shown to play an important role in bringing 
the binding partners together, affecting the kon rates (53, 54). Off-rates, on the other hand, 
are thought to be affected by short-range interactions which lock the two molecules 
together (53). The UCA as measured by the SPR demonstrated a 3-fold higher on-rate than 
the MAAb. The L-E55 residue of UCA can form a salt bridge with PA-R178, which 
interestingly is lost in MAAb where the residue moved further away from the arginine. The 
long-range electrostatic interaction between these two residues can be expected to be 
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weaker in MAAb and this might have played a role in the on-rate decrease. The positively 
charged residues L-K50 and PA-R178 are close in space. While their orientations are 
opposite in the bound complex and hence they can form a hydrogen bond, the positive 
charges could potentially repel each other while the two proteins are approaching each 
other. The HAAb has a 5-fold higher on-rate than the MAAb. The H3 loop salt bridge in 
MAAb is broken in the HAAb due to the H-K98Q mutation. This frees up the H-106D 
residue and along with loop preorganization and reorientation of the heavy and light chains, 
brings the residue closer to PA-R178. The new conformation also allows the L-E55 to 
interact with PA-R178, forming a triad salt bridge among these three residues. In addition, 
L-K50 can form a salt bridge with PA-E224. The ability to form these salt bridges might 
have contributed to the increase in the on-rate. Overall though, the on-rates of the three 
antibodies are quite similar and fast, which might be due to maintaining the majority of the 
charged residues during affinity maturation. 
Unlike the small changes in the on-rates, the off-rates decrease nearly 100-fold from the 
UCA to the MAAb, and another 100-fold from the MAAb to the HAAb. An important 
mutation during affinity maturation of this clone seems to be L-Y94F which is incorporated 
very early in the phylogenetic tree, just after the UCA, and is preserved in all the clone 
members except one, which does not survive. The tyrosine in this position is in a steric 
clash with PA-T516, which might prevent the antibody from coming close to the antigen 
to form short-range interactions. With the steric clash removed upon the mutation of the 
94th residue into phenylalanine, the MAAb now can come closer to the antigen, allowing 
better short-range interactions between the proteins which is reflected by the increase in 
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the magnitude of the favorable enthalpy and contributing to a more stable complex 
formation, hence smaller off-rates. The further decrease in the off-rates can be attributed 
to the change in the variable domain orientations, allowing better contacts as well the 
formation of new interactions with the antigen for stronger complex formation. The 
improvement in the enthalpy supports this interpretation. 
In terms of the changes happening in dynamics during affinity maturation, the decrease in 
the dynamics of the paratope periphery might help with better presenting the CDR loops 
to the antigen. The CDR-H3 loop becomes less dynamic in the HAAb, which might 
stabilize the interactions formed between the loop and the antigen and increase the affinity. 
Domain 1 of the antigen, with which the H3 loop interacts, forms several salt bridges, 
hydrogen bonds and van der Waals interactions with various regions of the antibody. 
Interestingly, CDR-H2 region becomes more dynamic with affinity maturation. A similar 
mixed pattern of dynamics changes was observed with molecular dynamics simulations of 
4 mature/germline antibody-antigen pairs (105), although they did not observe increased 
dynamics for CDR loops involving contact residues. While we cannot rule out the 
possibility that the increase in dynamics is an unintended consequence of the mutations 
affecting the global stability, CDR-H2 interacts with a flexible loop of the domain 3 of the 
PA by hydrogen bonding and van der Waals interactions. In general, higher rigidity has 
been suggested to increase affinity; however, it has also been suggested that flexible 
regions prefer to interact flexible counterparts and this can act as a mechanism to increase 
affinity (106). Therefore, the increase in the transient fluctuations of the CDR-H2 might be 
actually contributing to the affinity increase observed for the HAAb by giving the H2 loop 
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more chances to interact with the corresponding flexible domain 3 loop. 
In summary, this study provides insight into how an affinity maturation pathway might 
lead to very high affinities, and has implications for vaccine and therapeutic antibody 
design. 
 
6.4. Significance. 
This study has implications for vaccine and antibody development. The FDA protocol for 
Anthrax Vaccine Adsorbed requires five immunizations, but we have clearly seen that 
maximum affinity maturation is achieved after the third immunization. If it were possible 
to remove the last two immunizations, it would be great relief to the people who receive 
the shots, in addition to the financial gains that would be obtained through eliminating two 
shots.  
The fast on-rates of the unmutated ancestors and other members of the clones suggest the 
importance of on-rates during successful clonal expansion. Designing immunogens that 
can bind to naïve B-cell receptors with fast on-rates can increase the chances of those B 
cells to proliferate and reach high affinities. 
High affinities can be achieved by forming noncovalent interactions with the antigen, better 
complementarity between the antibody and the antigen, and structural pre-organization in 
the unbound state, minimizing entropy loss upon binding. In the development of 
therapeutic and diagnostic antibodies, improvements in both enthalpy and entropy are 
needed to reach high affinities. Most often, improvement in one of these parameters is 
counteracted by deterioration in the other parameter. A stepwise mechanism, as observed 
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for our antibodies, might guide rational design approaches.  
Protein dynamics is known to play a significant role in binding. Dynamic changes vary 
throughout the protein during affinity maturation. The stability increase in some regions 
and the increased dynamics in the other regions might be balancing each other. While 
increased dynamics can adversely affect specific binding, increased stability might be 
entropically unfavorable. As a result, having both might be more favorable for designing 
therapeutic antibodies. One of the strategies to improve protein stability and function in 
antibody design is to rigidify flexible regions. Rigidification efforts accompanied by the 
introduction of alternating dynamic regions can aid the development of stable, specific and 
high affinity molecules.  
 
6.5 Future Directions. 
Studying affinity maturation of various antigen-antibody pairs has demonstrated several 
mechanisms contributing to the affinity increase. However, none of the studies until now 
have investigated affinity maturation in a comprehensive manner, where several antibodies 
from distinct clones that arise against the same antigen exposure are characterized in detail 
with various experimental and computational techniques. It would be highly interesting to 
see whether different branches from the same clone mature similarly, whether different 
clones from the same donor follow similar evolutionary pathways, and how the immune 
response from different donors differs in terms of affinity maturation.  
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6.6 Study limitations. 
The antibodies we characterized were based on B cells isolated from donors vaccinated 
several times. While this provided us the tremendous opportunity to study affinity 
maturation of real-life sequences in a longitudinal manner, we were not able to functionally 
characterize the roles of individual mutations but rather observe the overall effects of the 
accumulated mutations. However, relying on the crystal structures and biochemical 
knowledge, we suggested roles regarding how the mutations might be affecting the 
antibody-antigen interaction. The UCA and MAAb did not form crystals in complex with 
the antigen during the study period. As antibodies from the same maturation pathway have 
been demonstrated several times to target the same epitope, we presumed the UCA and 
MAAb would target the antigen in the same way as the HAAb does and drew our 
conclusions based on this presumption. ITC requires several optimization trials and large 
amounts of samples in milligram levels. Due to the difficulty of producing enough material 
for replicate experiments, we could only do the ITC experiments once per sample. This is 
a common issue for ITC experiments, especially when studying protein-protein 
interactions as expressing proteins in high quantities is usually a challenging task. 
However, Kantonen et al. demonstrated the reliability of ITC in measuring the binding 
enthalpies, with 1% uncertainty determined for noise in the injection heat at 27°C (79). 
Therefore, the differences between the enthalpy values of the antibodies can be deemed 
significant. We also obtained affinity values comparable to the values obtained via SPR, 
confirming the affinity data. HDX-MS is a powerful technique to characterize the dynamics 
of proteins; however, its resolution is limited to a few amino acids at best. The peptides 
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obtained rely on the digestion pattern of the restriction enzyme used, pepsin in our case, 
which cuts the antibodies at different locations due to sequence differences. While we got 
decent coverage of the sequences, we were unable to obtain comparable peptides for each 
region, complicating the comparison efforts. A strategy to overcome this issue can be to 
use a mixture of different enzymes to increase the cut sites. 
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